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The work contained herein sought to combine soluble extracellular matrices (ECMs) derived 
from decellularized musculoskeletal tissues with biomimetic scaffolds for the purpose of 
orthopaedic tissue engineering.  More broadly, tissue engineering combines cells, scaffolds, and 
biomolecules (e.g., growth factors and cytokines) to restore or replace biological tissues. 
Scaffolds derived from decellularized tissues provide cells with the biophysical and biochemical 
motifs that constitute the ECM of the native tissue, in turn promoting homologous (i.e., tissue-
specific) cell phenotypes.  However, decellularized whole tissues are limited in clinical use due 
to poor cell infiltration and constrained geometries.  On the other hand, decellularized tissues can 
be pulverized or solubilized to theoretically provide a tissue-specific supplement that, in 
combination with biomimetic scaffolds, promotes homologous neotissue formation in a tissue 
defect regardless of shape or size. Nevertheless, the retention of tissue-specific bioactivity 
following solubilization of ECMs remains uncertain.  In particular, few studies have explored the 
tissue-specific bioactivity of soluble ECM derived from decellularized musculoskeletal tissues. 
In this thesis, tendon, hyaline cartilage, and knee menisci were decellularized and 
solubilized through one of two methods – (1) urea extraction or (2) pepsin digestion.  When 
added as medium supplements to in vitro cultures of human mesenchymal stem cells (MSCs) 
grown on two-dimensional (2D) plastic or as 3D MSC pellets, only urea-extracted ECM 
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 v 
fractions promoted tissue-specific differentiation.  Urea-extracted fractions of ECM derived from 
the inner and outer halves of the meniscus exerted region-specific effects, in agreement with the 
regional variations in ultrastructure, biochemical composition, and cell phenotype seen in native 
menisci.  The soluble ECMs further enhanced tissue-specific differentiation when combined with 
biomimetic scaffolds, including aligned electrospun nanofibers to mimic tendon and 
photocrosslinkable hydrogels to mimic hyaline cartilage and inner meniscus.  Additionally, 
soluble ECMs interacted synergistically with transforming growth factor beta (TGF-β) when 
provided as an exogenous supplement.  Taken together, the work contained herein begins to 
elucidate the mechanisms by which soluble ECMs promote tissue-specific effects and provides 
support for their use in orthopaedic tissue engineering.  
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1.0  INTRODUCTION 
The musculoskeletal system is broadly divided into hard (bony) and soft tissues, with injury to 
these tissues constituting one of the most common causes of pain and disability. The etiology of 
musculoskeletal disease ranges from acute trauma to chronic degeneration. Treatment options 
span temporary activity restriction through total tissue replacement (e.g., meniscal allograft 
transplantation, osteochondral allograft transplantation, etc.).  However, barring extensive co-
morbidities (e.g., diabetes, chronic smoking, etc.) or massive tissue loss, injuries involving bone 
typically heal with complete restoration of bony structure and function.  Conversely, orthopaedic 
soft tissues, including muscle, tendon, ligament, hyaline (i.e., articular) cartilage, and 
fibrocartilage (e.g., menisci, labrum, intervertebral discs), possess a poor intrinsic healing 
capacity.  Also in contrast to bone, orthopaedic soft tissues generally have a limited blood supply 
and are relatively hypocellular, as individual cells are separated by dense extracellular matrix 
(ECM).  The intraarticular location of many soft tissues may also contribute to their weak 
healing potential, as the synovial fluid contains fibrinolytic enzymes that degrade the provisional 
fibrin clot of early wound repair.1 When healing does occur, it is through a process of scar 
formation. The healing tissue possesses a disorganized ultrastructure and dysregulated 
biochemical composition.  Even following years of remodeling, the structure and function of the 
injured tissue is not restored to its native quality, resulting in sustained dysfunction and possible 
pain.  Surgical treatment of ruptured soft tissues may successfully restore continuity of the torn 
 2 
ends, yet biological limitations impede successful outcomes.  As a result, there have been 
increasing efforts to enhance soft tissue healing by manipulating the innate healing response.   
“[Tissue engineering] applies the principles of engineering and life sciences toward the 
development of biological substitutes that restore, maintain, or improve biological tissue or 
whole organ function.”2 In an effort to recapitulate the structure and function of native tissues, 
engineered constructs are comprised of cells, scaffolds, and biomolecules (e.g., growth factors, 
cytokines, etc.).  The use of autologous cells obviates an adverse immune response induced by 
foreign cells of allografts or xenografts, but mature cells of musculoskeletal soft tissues (e.g., 
chondroctyes, tenocytes) are not available in large numbers due to the accompanying iatrogenic 
defect and frequently undergo rapid dedifferentiation upon expansion on culture plastic.3 
Alternatively, mesenchymal stem cells (MSCs) are adult stem cells of the perivascular niche that 
are abundantly available from multiple tissue sources (e.g., bone marrow, adipose) and are 
capable of differentiating into all mature cell lineages of the musculoskeletal system.4,5 As a 
result, MSCs have been combined with biomimetic scaffolds and biomolecules germane to the 
development of a particular tissue in an effort to recapitulate the structure and function of native 
tissue.  Unfortunately, the ECM of native tissue is highly complex, rendering current capabilities 
to faithfully engineer the combined biophysical and biochemical motifs of native tissues 
exceedingly difficult.  On the other hand, decellularization of allografts or xenografts could 
mitigate immune rejection while preserving the ultrastructural and biochemical cues of native 
tissues, providing a scaffold capable of directing tissue-specific differentiation of endogenously 
recruited or exogenously seeded progenitor cells.6,7 
However, the application of scaffolds derived from decellularized musculoskeletal ECMs 
is not without challenges.  The dense ECM ultrastructure that imparts the unique function of 
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musculoskeletal soft tissues can necessitate relatively harsh decellularization methods, which 
may compromise the ultrastructure and biochemical composition of native tissues.  Even with 
sufficient decellularization, infiltration of recruited or seeded cells is often limited, with cells 
remaining on the graft surface.8,9 Likewise, grafts of decellularized whole tissue require invasive 
reconstruction/replacement procedures and the material properties of the graft are relatively 
immutable.  In contrast, tunable biomaterials, including electrospun nanofibers and hydrogels, 
can be engineered to mimic the ultrastructure and mechanical properties of a particular 
musculoskeletal tissue while also permitting greater flexibility in terms of controlling 
degradation rates, cell migration/infiltration, and release of encapsulated growth factors.  
Nevertheless, the biomolecules traditionally incorporated into biomimetic scaffolds are far fewer 
than the diverse array of proteins that comprise native tissue and impart a particular phenotype to 
resident cells.  Consequently, the following work has sought to combine soluble extracts of 
decellularized musculoskeletal tissues with tissue-specific biomimetic scaffolds to more fully 
recapitulate the native biochemical and biophysical cues that mediate tissue-specific cell 
phenotypes.  This approach has been applied to three tissues that comprise a large percentage of 
the musculoskeletal disease burden – (1) tendon/ligament, (2) articular (hyaline) cartilage, (3) 
knee meniscus. 
1.1 ORTHOPAEDIC SOFT TISSUES 
1.1.1 Tendon and Ligament 
The following section contains material from the publication: 
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Rothrauff BB, Yang G, Tuan RS. 2015. Tendon Resident Cells - Functions and Features in 
Section I - Developmental Biology and Physiology of Tendons. In: Gomes ME, Reis RL, 
Rodrigues MT (editors). Tendon Regeneration - Understanding Tissue Physiology and 
Development to Engineer Functional Substitutes. London, UK: Elsevier; pp. 41-77. 
1.1.1.1 Structure and function  Tendon and ligament connect muscle to bone or bone to 
bone, respectively, providing both joint stability and translating muscular contractile forces into 
joint mobility.  Given their similar function, both tissues share a similar structure – a hierarchy of 
aligned collagen fibrils aggregated into aligned fibers with elongated fibroblasts (i.e., tenocytes) 
found in the interpositional region (Figure 1).10 Mature tenocytes express the transcription factor 
Scleraxis (Scx)11,12 and the cell surface glycoprotein Tenomodulin (Tnmd).13,14 Tendon and 
ligament are principally composed of collagen type 1, but additional collagen types and 
proteoglycans play an essential role in orchestrating and maintaining tissue structure and 
function.15 Growth factors and latent metalloproteinases are also localized to the ECM, 
contributing to tissue homeostasis.  The hierarchical structure allows tendon and ligament to 
resist high tensile loads, with peak forces during running exceeding 12x bodyweight.16 Although 
there is heterogeneity among tendons and ligaments, most will fail with strains exceeding 15%.  
Nevertheless, when testing under uniaxial tension, all tendons and ligament exhibit a 
characteristic load-elongation (stress-strain) curve (Figure 2), divided into the following regions 
– (a) 0-2% strain = toe region, in which the crimp pattern is slowly removed, (b) 2-8% strain = 
linear region, in which there is a constant increase in load with a corresponding increase in 
elongation, (c) >8% strain = plateau, preceding macroscopic failure.17 
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Figure 1. Overview of tendon tissue architecture.  . Tenocytes reside between collagen fibers 
and deposit extracellular matrix proteins into the microenvironment. The proteoglycans, decorin, 
biglycan, fibromodulin, and lumican, are involved in collagen fibrillogenesis and stem cell niche 
maintenance. Besides proteoglycans, other types of glycoproteins are also important constituents 
of tendon for cell adhesion and structural integrity, such as fibronectin, cartilage oligomeric 
matrix protein (COMP), and lubricin. The collagen fibers are wrapped by a layer of connective 
tissue known as endotenon that contains blood vessels, lymphatics, and nerves.  
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Figure 2. Stress-strain behavior of tendon and ligaments.  When elongated under tension, 
tendons/ligaments exhibit three distinct regions in their stress-strain curves – toe (0-2% strain), 
linear (2-8% strain), and plateau (>8% strain).  Adapted with permission from Wang (2006).17 
1.1.1.2 Injury and intrinsic healing  Of the 32 million musculoskeletal injuries occurring 
annually in United States, ~45% involve tendon and ligament.18 While the incidence of injury 
differs across particular tendons and ligaments, none exhibits a healing response that restores 
native structure and function.  However, tendons and ligaments located extraarticularly (i.e., 
outside the joint), such as the Achilles tendon and the collateral ligaments of the knee, can be 
managed conservatively, while those located intraarticularly, such as the rotator cuff tendons of 
the shoulder and the cruciate ligaments of the knee, display a negligible healing response.1,19 As 
a result, intraarticular tendon and ligament injuries require surgical intervention to restore tissue 
continuity.  In particular, over 100,000 anterior cruciate ligament (ACL) reconstructions are 
performed annually,20 as are 300,000 rotator cuff repairs.21 When intrinsic healing does occur, as 
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seen with tears of the medial collateral ligament (MCL), the process is one of generic wound 
healing, with sequential but overlapping inflammatory, proliferative, and remodeling phases.22 
The resulting neotissue is a hypertrophic scar with disorganized collagen fibril architecture and 
perturbations in biochemical composition (Figure 3), resulting in sustained decrements in 
mechanical properties.  While numerous growth factors have been identified in this process,23 in 
remains uncertain how their manipulation might permit scarless healing, or at minimum, the 
restoration of native structure and function.24 
 
 
 
 
 
 
 
 
 
Figure 3. Intrinsic healing response of tendon and ligament. H&E stained section of the 
interface of native (normal) tendon and the disorganized scar (repair) that forms 12 weeks 
following removal of the central third of the patella tendon in a rabbit model. 
1.1.1.3 Current treatment approaches  The ideal treatment strategy for tendon and 
ligament tears is context dependent, taking into consideration not only the aforementioned 
differences in the intraarticular and extraarticular microenvironments, but also the state of health 
of other musculoskeletal tissues and the patient as a whole.  For instance, isolated tears of the 
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MCL are more frequently repaired than are MCL tears in the context of a combined ACL tear.25 
In particular, an ACL reconstruction will render the patient non-weight bearing for several post-
operative weeks, protecting the intrinsic healing response of the MCL.  Furthermore, there is 
evidence that the MCL actually heals better in the presence of an ACL reconstruction, 
presumably due to a greater healing response elicited by concurrent injury.   Regardless of the 
chosen conservative or surgical approach to treat a given tendon or ligament injury, biological 
impediments still exist.  To date, no tissue engineering strategy has become standard of care for 
tendon and ligament injuries. While there are have been numerous case series on the application 
of tissue-derived scaffolds for augmented repair of large to massive rotator cuff tears, only two 
prospective, randomized trials have been performed, with conflicting results.26,27 Given the 
paucity of high quality data, coupled with early reports of sterile inflammation, the American 
Academy of Orthopaedic Surgeons does not currently advocate the use of biologic scaffolds in 
the management of rotator cuff tears.28 Clinical studies examining the efficacy of cell therapies 
in enhancing tendon and ligament healing are even rarer, although there are some promising 
findings for the application of exogenous MSCs in rotator cuff repair.29  
1.1.2 Articular Cartilage 
1.1.2.1 Structure and function  Articular (hyaline) cartilage covers the ends of bone at a 
joint and serves to distribute loads and allow low friction gliding of articular surfaces.  While 
hyaline cartilage contains a single cell type, the chondrocyte, the osteochondral unit possesses a 
hierarchical structure.  Namely, when moving from superficial to deep, there are four zones – (1) 
superficial tangential, (2) middle transitional, (3) deep radial, and (4) calcified cartilage (Figure 
4).30 Collagen type 2 accounts for 90-95% of all collagen in hyaline cartilage, with the fibrils 
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organized in different orientations depending on region.  Proteoglycans (e.g. hyaluronan, 
aggrecan, chondroitin/dermatan sulfate, etc.) also comprise a large portion of the cartilage mass, 
with these highly charged aggregates forming non-covalent bonds with water, thereby allowing 
cartilage to function in force dissipation.31 In addition, hyaluronan and proteoglycan 4 (lubricin) 
are found at high concentrations in the superficial region and serve to minimize friction between 
articulating surfaces.32 Devoid of blood vessels, lymphatics, and nerves, chondrocytes of hyaline 
cartilage are nourished through (hydrostatic) pressure-mediated fluid shifts, as occur with joint 
motion.  Since cartilage can be several millimeters thick, there are both nutrient and oxygen 
gradients across regions, which can influence chondrocyte behavior.33 
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Figure 4. Hierarchical structure of osteochondral unit. Adapted with permission from 
Gadjankski & Vunjak-Novakovic (2015)30 
1.1.2.2 Injury and intrinsic healing   As of 2005, an estimated 27 million people in the 
United States had symptomatic joint degeneration (i.e., osteoarthritis, OA), a number expected to 
rise with an aging population.34 While ~10% of the population truly constitutes a large disease 
burden, treating osteoarthritis in the context of an aged joint is a highly formidable challenge, 
given the diffusivity and chronicity of disease, coupled with systemic impairments in healing 
experienced with aging.  On the other hand, 12% of osteoarthritis is attributable to a distinct 
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traumatic event (i.e., post-traumatic OA), which is seen more commonly in young patients with 
healthy joints, excluding the focal chondral defect.35 Therefore, most of the early efforts to 
enhance cartilage healing (and subsequent efforts in cartilage tissue engineering) have focused 
on treating focal lesions, as discussed below. 
The hypocellularity and absence of vasculature in cartilage has traditionally been cited to 
explain the poor intrinsic healing capacity of articular cartilage.  Furthermore, it has long been 
believed that cartilage lacks any stem/progenitor cell population that could aid in tissue repair.  
However, recent studies have cast doubt on this dogma.  Sekiya et al.36 found an increase in 
MSCs within the synovial fluid of osteoarthritic joints, as compared to healthy knees, and the 
MSC number positively correlated with the severity of cartilage degeneration.  Similarly, Jiang 
et al.37 reported on the emergence of a multipotent cartilage stem/progenitor cell as a 
subpopulation of culture expanded mature chondrocytes.  While the role that these putative 
progenitor cells play in vivo remains unclear, clinical evidence clearly demonstrates that any 
intrinsic healing response of cartilage is insufficient to prevent joint degeneration following acute 
trauma or with age.38 
1.1.2.3 Current treatment approaches  Age-associated OA follows a slow, insidious 
progression, ultimately causing the patient to present to the clinic complaining of diffuse joint 
paint made worse with duration and intensity of activity.  At present, the standard of care 
involves analgesics (i.e., oral non-steroidals through intraarticular corticosteroid injections) and 
possible physical therapy to strengthen the surrounding muscles.  However, upon failure of 
conservative treatment, total joint arthroplasty is typically recommended.  Conversely, focal 
chondral defects in relatively healthy joints have been treated surgically over the past several 
decades.  Namely, microfracture is a procedure in which the subchondral bone of the lesion is 
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punctured with small holes to allow blood (and with it, progenitor cells) to form a clot and 
initiate a generic wound healing response.  While microfracture produces a fibrocartilaginous 
neotissue that improves both pain and function in the short-term, the inferiority of this tissue to 
that of native hyaline cartilage ultimately leads to continued joint degeneration.39 
In an effort to promote a more hyaline phenotype, autologous chondrocyte implantation 
(ACI) was developed.  ACI is a two-step procedure in which cartilage from a non-weightbearing 
region is isolated in the first procedure.  The cartilage is enzymatically digested to liberate the 
chondrocytes, which are then expanded and subsequently re-implanted as a cell suspension into 
the focal defect.  The defect is then covered by a collagen-based membrane that is sutured to the 
cartilaginous ring of the surrounding, healthy cartilage.40 After undergoing several iterative 
changes, clinical results have shown promise, yet challenges still exist.  In particular, promoting 
and maintaining a stable (hyaline) chondrogenic phenotype remains a major hurdle.3 For reasons 
that are not entirely known, chondrocytes of the neotissue often drift towards a 
fibrochondrogenic phenotype, as seen with microfracture, or undergo hypertrophy in a process 
recapitulating endochondral ossification.41-43 
Further adaptations of ACI have been reported, seeking to maintain a more stable 
chondrogenic phenotype and/or provide greater mechanical stability (and construct integrity) 
than a cell suspension covered with a membrane.  Other products, utilizing allogeneic 
chondrocytes or autologous chondrocytes co-cultured with bone marrow cells, seek to obviate 
the need for a two-step procedure.44 While these qualities must certainly be addressed in order to 
make cell-based therapies the standard of care for focal chondral defects, comparisons among 
products are limited at present by small sample sizes, low-quality clinical studies (i.e., case 
series), and non-standardized reporting on outcomes.45   At the same time, and in recognition of 
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OA as a disease of the osteochondral unit,46 tissue engineers have begun to fabricate composite 
constructs with zonal organization mimicking the native osteochondral unit.30,47,48 Clinical 
application of these novel constructs are only in the earliest stages. 
1.1.3 Meniscus 
1.1.3.1 Structure and function  The menisci of the knee are crescent-shaped 
fibrocartilaginous structures interposed between the femoral condyles and tibial plateau.49 
Functioning under a demanding mechanical loading environment of compressive, tensile, and 
shear stresses, the menisci have a complex, region-specific structure.50,51 The inner region of the 
meniscus, when loaded by the articulating femur and tibia during locomotion, experience 
compressive forces that are translated through radial tie fibers to aligned circumferential collagen 
1 fibers of the meniscus periphery.51,52 Therefore, there is a gradient from the collagen 2- and 
proteoglycan-rich inner regions towards the collagen 1-rich outer regions.53-55 The regional 
variation in structure and biochemistry corresponds to regional differences in cell phenotype – 
cells of the inner region possess a round morphology and gene expression profile similar to 
articular chondrocytes while cells of the outer region are interposed between aligned collagen 
fibers and exhibit a fibroblastic phenotype.56 
Once thought to be a vestigial tissue, the meniscus is now recognized to be vital to joint 
health, and in particular, to maintaining the integrity of articular cartilage (i.e., preventing OA).  
As early as 1948, Fairbank57 demonstrated that the complete removal of the meniscus (i.e., total 
meniscectomy) produces instantaneous joint space narrowing in the affected compartment, with 
subsequent loss of articular cartilage.  Fairbank speculated that these destructive changes were 
attributable to decreased contact surface area, and increased contact stresses, resulting from 
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meniscectomy.  Krause et al.58 confirmed this impression of altered dynamics in 1976 through 
biomechanical testing of cadaveric models.  Given the catastrophic consequences of total 
meniscectomy, orthopaedic surgeons thereafter sought to preserve meniscus tissue volume.  This 
approach is further support by recent cadaveric studies.  Bedi et al.59,60 showed that changes in 
contact stresses, depending on tear morphology, are not seen until the tear size becomes quite 
large (e.g., 90% the width of the meniscus for radial tears), corroborating the importance of 
preserving tissue volume. 
1.1.3.2 Injury and intrinsic healing  The meniscus is the most commonly injured 
structure of the knee, resulting in over 1,000,000 meniscal procedures performed annually.61 
Much like articular cartilage, the inner 2/3rd of the meniscus is avascular, imparting a limited 
healing potential on this region.  Unfortunately, the avascular region is where the majority of 
tears occur.62 When meniscal explants are cultured ex vivo, the emerging cells are capable of 
forming colonies and undergoing multi-lineage differentiation, suggested either resident 
meniscal stem cells or dedifferentiation upon culture expansion.63 Similarly, increased 
concentrations of MSCs are found in the synovial fluid after meniscus injury.64 Nevertheless, 
inconsistent spontaneous healing of tears in the avascular region is seen clinically.  In addition, 
an aberrant phenotype of meniscal cells in seen in the degenerated joint, with a predisposition to 
undergo osteogenesis.65 Given the importance of the meniscus in joint integrity, coupled with a 
growing interest in biologics, primary repairs of meniscus tears are increasingly performed.66 
1.1.3.3 Current treatment approaches  Despite the recent trend to repair isolated meniscus 
tears,66 the standard of care remains a partial meniscectomy for tears in the avascular region.  
Meniscal allograft transplantation is a viable option for a narrow patient population; in particular, 
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a young, thin patient with neutral knee alignment, healthy articular cartilage, intact (or 
concurrently repaired) knee ligaments, yet symptomatic meniscus deficiency.61 In order to 
expand the number of patients eligible for primary meniscus repair, novel surgical approaches 
and suture techniques are being actively investigated.67-69 Some of these techniques have since 
been translated to the operating room in a limited number of cases.70,71 
Given the absence of vasculature in the inner meniscal region, surgeons will often place 
an autologous blood (i.e., fibrin) clot in the defect when performing a repair.  While this 
approach showed early promise in animal models,72 it has yielded equivocal benefit clinically, 
possible due to a rapid disintegration by fibrinolytic enzymes of synovial fluild.1 The provision 
of vascular channels from the periphery to the tear site (i.e., trephination) has also shown mixed 
results.73,74 The application of PRP, while sporadically employed, has also not demonstrated 
conclusive benefit.75 Conversely, cell therapies have broadly shown promising results in large 
animal models,76,77 yet only one human clinical study has been performed in which adipose-
derived MSCs were injected intraarticularly following subtotal meniscectomy.78,79 
1.2 MUSCULOSKELETAL TISSUE ENGINEERING 
The following section contains material from the publication: 
Yang G, Rothrauff BB, Ling H, Gottardi R, Alexander P, Tuan RS. 2015. Enhancement of 
tenogenic differentiation of human adipose stem cells by tendon-derived extracellular matrix.  
Biomaterials 34(37): 9295-9306.  
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Figure 5. The elements of tissue engineering. Native tissues are comprised of cells and the 
extracellular matrix, which contains both biophysical and biochemical cues.  In combining 
biomimetic scaffolds with tissue-derived soluble ECMs, it may be possible to replicate the 
biophysical and biochemical motifs, respectively, of native tissues.  These novel biomaterials 
may then be seeded with patient-derived MSCs to provide an autologous, engineered construct 
for implantation. 
 
Musculoskeletal tissue engineering, as with all tissues and organs, combines cells, scaffolds, and 
biomolecules, in an effort to reconstitute the essential elements of native tissue.2 In native 
tissues, the ECM provides both biophysical and biochemical cues to the resident cells, which in 
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turn modify the ECM to maintain homeostasis (Figure 5).   Thus, cells and ECM exist in a 
relationship of dynamic reciprocity.6,80 Biomimetic scaffolds can be engineered to mimic the 
topographical and mechanical properties of the ECM.  Although polymeric materials most 
commonly utilized for scaffolds are biocompatible, they often lack the bioactive motifs inherent 
to natural ECM proteins.  At the same time, supplementation with exogenous biomolecules (i.e, 
growth factors) is needed for robust cell differentiation and protein synthesis, yet these growth 
factors have pleotropic effects that can result in heterologous cell phenotypes. 
Alternatively, scaffolds derived from decellularized tissues theoretically possess the 
precise biophysical and biochemical cues that comprise the resident cell niche.  However, ECM-
derived scaffolds have several unique limitations, as outlined below, which prevent wider 
clinical application.  Soluble solutions of decellularized ECM have been recently explored to 
overcome several of these limitations, yet their ability to promote homologous (i.e., tissue-
specific) cell phenotypes remains underexplored.  The strengths and weaknesses of biomimetic 
scaffolds and those derived from ECM will be described in sequence with the intention of 
combining these biomaterials to capture their respective advantages while overcoming their 
limitations. 
1.2.1 Decellularized Extracellular Matrix as a Biomaterial 
Far from being a passive ‘ground substance’, as previously considered, the ECM actively 
communicates with the resident cells.  The ECM is so rich in bioactive information that 
decellularized whole organs have sustained systemic physiological function when transplanted 
into animal models following recellularization and pre-conditioning in bioreactors.81-83 Although 
whole organs are complex systems with multiple cell types, whose interactions are coordinated 
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across time and space, the decellularization protocols that must be employed for sufficient 
removal of their cellular content are more mild than those required to decellularize dense 
connective tissues.6,84 Not only does the dense collagenous architecture prevent permeation of 
cytolytic agents and subsequent extraction of cellular remnants, these tissues are also 
hypovascular, providing fewer conduits through which the decellularizing agents may be 
perfused.  Nevertheless, several protocols have been shown to successfully decellularize tendon, 
cartilage, and meniscus, which can be used as (whole) tissue grafts or further processed by 
milling and solubilization.  Each form of decellularized ECM presents unique advantages and 
limitations, as discussed below. 
1.2.1.1 Whole tissue ECM Large explants of tendon, cartilage, and meniscus have been 
decellularized using assorted protocols, though most include a detergent (e.g., Triton X-100, 
Sodium Dodecyl Sulfate, etc.) with possible nuclease treatment to follow.84-86 Decellularization 
of the whole tissue has been most commonly explored for tendon, with several studies 
demonstrating the preservation of aligned collagen ultrastructure following decellularization.85,87-
90 The scaffolds are capable of supporting cellular attachment, proliferation, and elongation 
(parallel to collagen fibers), with corresponding upregulation of tenogenic markers.85,89,90 The 
preservation of ultrastructure results in negligible reductions in tensile properties,88 but highly 
aligned collagen fibers yield poor suture retention strength, perhaps limiting surgical 
applicability especially if the graft is intended for mechanical augmentation.91,92 
Alternatively, decellularization has been found to diminish the compressive modulus of 
hyaline cartilage ECM, likely due to a significant loss of proteoglycan content.8,93 Seeded cells 
are capable of upregulating a chondrogenic phenotype with corresponding deposition of 
cartilaginous ECM proteins (e.g., Collagen type 2, proteoglycan), but this anabolic effect is 
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dependent on culture supplementation with exogenous transforming growth factor beta, TGF-
β.8,84,93 Similar observations have been reported for decellularized menisci, although only a few 
studies have been performed to date.86,94 Regardless of the proteoglycan loss, decellularized 
whole cartilage ECM exhibits minimal cell infiltration, with cells localized to the explant 
surface.8,93 Limited cell infiltration may adversely affect graft remodeling and integration with 
native tissues, perhaps explaining the high failure rate of decellularized osteochondral allografts 
when applied clinically to focal cartilage lesions.95 Of further concern, limited cell infiltration 
has also been noted for decellularized whole tendon9,88 and meniscus.86 
1.2.1.2 ECM Powder      In order to improve cell infiltration and surgical applicability, as 
needed for small and/or irregularly shaped defects, the decellularized ECM can be milled into a 
powder.  In a series of related studies, Guilak and colleagues fabricated scaffolds of 
mechanically homogenized cartilage ECM fragments.96-98 When seeded with MSCs, these 
constructs supported chondrogenic differentiation and matrix deposition, effects that were 
enhanced with TGF-β supplementation in the culture medium.96 However, non-crosslinked 
scaffolds underwent cell-mediated contractions, limiting their applicability as space-filling 
constructs, as would be required for repair of focal chondral defects.96 Chemical or physical 
methods of crosslinking were able to preserve construct area,96,97 but increasing crosslinking 
density lead to decreasing chondroinductivity of the scaffold.97 Through optimization of the 
crosslinking agent and density, as well as the concentration of cartilage-derived matrix, 
anatomically-shaped constructs could be molded.98 However, the compressive mechanical 
properties of the constructs were still significantly inferior to native cartilage.98In similar but 
independent studies, Almeida et al.99-101 fabricated scaffolds of cartilage derived ECM powder 
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through freeze-drying,100 dihydrothermal crosslinking,99 or mixing with fibrin hydrogels.101 The 
ECM powder alone supported chondrogenesis of seeded MSCs, but robust chondrogenesis again 
required TGF-β supplementation.  In applying a similar approach to tendon and ligament tissue 
engineering, Dianne Little’s group has mixed pulverized ECM with collagen hydrogels102 or 
used it to coat electrospun nanofibrous scaffolds.103 Compared to studies examining cartilage 
ECM powder, the effects of tendon/ligament ECM powder were less inspiring, as these powders 
had little to modest effects on tenogenic differentiation of seeded MSCs.102,103 With several 
differences in experimental design, it is not possible to explain the minimal effects of the 
tendon/ligament powder when applied as a tissue-specific bioactive agent. 
1.2.1.3 Soluble ECM  Although pulverization of ECM improves cell distribution and 
expands the forms through which ECM can be incorporated into scaffolds, the constructs must 
be crosslinked within geometrically defined molds, with a subsequent in vitro culture period 
required for cell infiltration and attachment.  To overcome these limitations, further processing 
of decellularized ECM into soluble solutions has been explored.  Pepsin digestion of ECM in a 
mildly acidic solution yields a viscous slurry that self-polymerizes when neutralized and heated 
to body temperature.104 Pepsin digests of tendon,105,106 cartilage,107,108 and meniscus109 have been 
reported, with all studies noting excellent cytocompatibility.  However, few studies have 
investigated the tissue-specific bioactivity of these hydrogels despite this putative property being 
the basis for the use of homologous ECM.  Pati et al.107 reported a very modest (~1.5 fold) 
increase in Sox9 and Col2 expression in cells seeded in pepsin-digested cartilage ECM, as 
compared to a purified collagen 1 hydrogel.  In similar studies, Beck et al.110 and Visser et al.111 
found negligible tissue-specificity of pepsin-digested tendon, cartilage, or meniscus.  It is 
possible that pepsin, a non-specific protease, cleaves many of the bioactive proteins of the ECM 
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that are essential for imparting tissue-specificity.  SDS-PAGE gels of pepsin-digested ECM 
support this hypothesis, with few bands found outside of those corresponding to collagen 
chains.107,112  
On the other hand, Zhang et al.113 demonstrated that 2D culture dishes coated with urea-
extracted fractions of liver, skeletal muscle, and skin ECM, promoted homologous cell 
phenotypes. Similarly, our lab found that the urea-extracted fraction of decellularized MSC 
sheets, as opposed to pepsin-digested preparations, enhanced MSC attachment, spreading, 
proliferation, migration, and multi-lineage differentiation.114 More recently, we showed that 
urea-extracted tendon ECM, when added to an MSC-seeded collagen hydrogel under static 
uniaxial tension, upregulated tenogenic differentiation while concurrently downregulating 
osteogenic markers, suggesting homologous bioactivity inherent in this soluble ECM preparation 
(Figure 6).115 Based upon these findings, it is possible that urea-extracted fractions of 
decellularized ECM derived from multiple musculoskeletal tissues can promote tissue-specific 
differentiation.  If so, these soluble ECM preparations may be combined with biomimetic 
scaffolds possessing topographical and mechanical properties of homologous tissues, providing a 
tissue engineered construct containing both the biophysical and biochemical motifs of native 
tissue.    
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Figure 6. tECM-enhanced hydrogels upregulate tenogenesis. (A-C) Human MSCs seeded in 
tECM-supplemented scaffolds (3D Collagen+ECM) show higher expression levels of tendon-
specific genes (SCX, TNMD, and TNC) compared to both pure collagen scaffolds (3D Collagen) 
and 2D culture group (2D). (D-F) Osteogenesis-related genes (RUNX2, ALP, and OCN) are 
expressed at lower levels in MSCs seeded in tECM-supplemented scaffolds compared to the pure 
collagen scaffold group, although some of them remain still higher than that in 2D culture. * 
indicates p < 0.05 compared to 2D; ** indicates p < 0.01 compared to 2D; # indicates p < 0.05 
compared to the other 3D group; and ## indicates p < 0.01 compared to the other 3D group; n = 
5 
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1.2.2 Biomimetic Scaffolds 
“Biomimetic scaffolds mimic important features of the extracellular matrix (ECM) architecture 
and can be finely controlled at the nano- or microscale for tissue engineering.”116 In engineering 
biologically relevant ECM motifs, cell behavior can be controlled for an intended purpose.117 
The repertoire of materials and methods used for engineering biomimetic scaffolds has rapidly 
expanded since the inception of tissue engineering.  While many have been explored for 
applications in musculoskeletal tissue engineering, nanofibers and hydrogels have been 
extensively utilized for tendon and cartilage engineering, respectively.   
1.2.2.1 Electrospun nanofibers  Electrospinning is a fabrication technique in which a 
viscous polymer (e.g., polyester) is pushed through a needle under high electrical charge and 
collected on a rotating mandrel that is electrically grounded.118    In controlling the parameters of 
electrospinning, mats of continuous fibers with particular geometries can be created.119 
Electrospun sheets of aligned nano- or microfibers have been exploited to mimic the aligned 
collagen fibers of the native tendon.120,121 Interestingly, electrospun fibers with an average 
diameter of several hundred nanometers (e.g., 320 ± 100  nm) promote greater cell proliferation 
those with a large diameter (1.8 ± 0.16 µm), which preferentially promote tenogenic 
differentiation.122 It is plausible that small diameter fibers mimic the immature collagen fibers of 
healing or developing tendon, a microenvironment in which cell proliferation would be needed, 
while large diameter fibers are reminiscent of mature tendon and therefore promote a mature 
tendon phenotype.123  
 Fiber orientation provides another instructive cue to seeded cells.  As compared to 
randomly oriented fibers, aligned fibers promote elongation of cells in a parallel direction, 
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resulting in upregulation of tenogenic markers and deposition of aligned ECM.124,125 Related 
studies have shown synergism between these biophysical cues and exogenous growth 
factors126,127 or mechanical stimulation,128 although cooperative effects have not been universally 
reported,129 with discrepancies likely attributable to variability in polymer composition, culture 
conditions, and micro- and meso-scale architectural cues.130 To date, no study has explored the 
possible synergism between aligned nanofibrous scaffolds and soluble tendon ECM. 
1.2.2.2 Hydrogels  Hydrogels are networks of crosslinked hydrophilic polymers capable of 
retaining high water content, bearing resemblance to the water-rich, interconnected 
collagen/proteoglycan network of hyaline cartilage.131 Polymers such as agarose and 
polyethylene glycol (PEG) can form 3D porous structures capable of maintaining cell sphericity 
and supporting chondrogenic differentiation, but these relatively bioinert molecules lack cell-
binding motifs of natural ECM proteins.131,132 In contrast, gelatin contains the bioactive motifs of 
native collagen while being highly water-soluble and capable of further functionalization.  In 
particular, the addition of methacrylate functional groups to the gelatin backbone, in the presence 
of a light-sensitive electron donor (i.e., photoinitiator), is capable of undergoing light-responsive 
crosslinking that results in a stable hydrogel.  These methacrylated gelatin (GelMA) hydrogels 
allow rapid encapsulation of cells and support robust transcriptional and translational 
upregulation of chondrogenesis.133,134 The addition of distinct cartilage ECM proteoglycans (e.g., 
hyaluronan, chondroitin sulfate, etc.) to GelMA hydrogels has been shown to further enhance 
chondrogenesis of encapsulated cells.135 However, the bioactive effect adding soluble cartilage 
ECM to GelMA hydrogels has not been investigated. 
Hydrogels have also been explored in the context of meniscus tissue engineering, but the 
majority of applications have sought to fabricate a whole engineered meniscus graft as opposed 
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to delivering cells to the tear site during surgical repair.136-138 In the few studies in which cell-
seeded hydrogels were used to augment suture repair, the hydrogel was made of a collagen 
slurry, which possesses weak mechanical properties and undergoes fast degradation.76,139 Given 
the homology of structure and biochemical composition between hyaline cartilage and the inner 
meniscal region, which possesses a poor intrinsic healing capacity but where most tears occur, 
the application of MSC-seeded GelMA hydrogels to meniscal tears may serve to enhance 
neotissue formation.  Further improvement may also be possible by enhancement the GelMA 
hydrogel with a soluble fraction of the inner meniscal ECM. 
1.3 RESEARCH OVERVIEW 
The overarching goal of the studies described hereafter is to develop a rational approach to 
musculoskeletal tissue engineering by combining the tissue-specificity inherent in decellularized 
extracellular matrix (ECM) with the versatility of engineered biomaterials.  The central 
hypothesis was that urea-extracted soluble ECM preparations derived from decellularized 
tendon, cartilage, and meniscus, would promote tissue- and/or region-specific differentiation of 
human mesenchymal stem cells (MSCs), thereby enhancing biomimetic scaffolds fabricated for 
orthopaedic tissue engineering.  The hypothesis was tested through the following specific aims: 
Specific Aim 1: Evaluate and compare the tissue-specific bioactivity of soluble tendon 
and cartilage ECM prepared through two methods – (a) pepsin digestion and (b) urea 
extraction 
Specific Aim 2: Evaluate the effect of combining soluble tendon and cartilage ECM with 
tissue-appropriate biomimetic scaffolds 
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Specific Aim 3: Evaluate the region-specific bioactivity of soluble inner and outer 
meniscal ECM when combined with biomimetic hydrogels. 
 
 These aims were addressed through experiments that ultimately comprise the content of 
four peer-reviewed publications.  The evaluation of tissue-specific bioactivity of soluble tendon 
and cartilage ECM (Aim 1) is described in Chapter 2. The benefit of enhancing biomimetic 
scaffolds with these soluble ECMs (Aim 2), and their synergistic effects with TGF-β 
supplementation, are described in Chapters 2 and 3. Finally, the region-specific bioactivity of 
soluble ECM derived from the inner and outer meniscal regions was explored in two 
photocurable hydrogels (Aim 3), the results of which are presented in Chapter 4. 
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2.0  TISSUE-SPECIFIC BIOACTIVITY OF SOLUBLE TENDON- AND 
CARTILAGE-DERIVED EXTRACELLULAR MATRICES 
2.1 INTRODUCTION 
Tendon and cartilage are commonly injured musculoskeletal tissues with a poor intrinsic healing 
capacity.  Tissue engineering strategies, which employ the independent or combined application 
of cells, scaffolds, or biomolecules, have shown promise in restoring the structure and function 
of both tendon140,141 and cartilage.39,142 Biomimetic scaffolds, including aligned electrospun 
nanofibers124,125 and hydrogels,134,143 possess ultrastructural motifs respectively found in native 
tendon and cartilage, which are capable of directing differentiation of mesenchymal stem cells 
(MSCs) towards a particular musculoskeletal lineage.  These effects are further enhanced by 
exposure to soluble biomolecules known to orchestrate tendon and cartilage 
development.127,131,144 In particular, the transforming growth factor beta (TGF-β) superfamily 
plays an essential role in both tenogenesis145 and chondrogenesis,146 mediating divergent effects 
depending upon additional microenvironmental cues.147 At present, an incomplete understanding 
of the biophysical and biochemical cues governing tendon and cartilage development and 
homeostasis preclude consistent regeneration of these tissues when employing the 
aforementioned tissue engineering approaches.3 
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On the other hand, tissues and organs can be decellularized to mitigate an adverse 
immune response against foreign cells while theoretically preserving the ultrastructural, 
mechanical, and biochemical motifs of the native tissue.6 To that end, decellularized tendon and 
cartilage may serve as the ideal scaffold to promote homologous (i.e., tissue-specific) 
differentiation of endogenously recruited or exogenously delivered progenitor cells.84,148 Indeed, 
decellularized tendon85,89,90 and cartilage8,93 tissues have been found to promote tissue-specific 
differentiation when seeded with MSCs.  Nevertheless, the dense collagenous architecture 
comprising the ECM of these tissues can necessitate the use of relatively harsh decellularization 
methods, which can compromise native tissue ultrastructure and biochemical composition.  Even 
with sufficient removal of cellular content, the dense ECM serves as a barrier for cell infiltration, 
with cells often localized to the tissue surface.8,9 In addition, the use of whole decellularized 
tissue as grafts requires surgical reconstruction/transplantation (as opposed to repair), with 
resulting limitations in treating small or irregularly shaped defects.   
In an effort to overcome these limitations while retaining the tissue-specific bioactivity 
inherent in the ECM, decellularized tissues have been processed into powders, which can be 
molded into distinct geometric shapes,96,98 or suspended in a hydrogel.100,101,110 Alternatively, 
ECM powders can be solubilized with enzymatic or chaotropic agents, resulting in an injectable 
solution that can be combined with a diverse array of biomaterials.  Pepsin-digested tendon105,106 
and cartilage108,149 hydrogels have been shown to undergo thermoresponsive gelation at body 
temperature and are cytocompatible.  However, the effect of pepsin, a non-specific protease, on 
the tissue-specific bioactivity of tendon and cartilage ECM remains unknown.  While Keane et 
al.150 reported that pepsin-digested esophageal ECM hydrogels supported esophageal stem cell 
migration and organoid formation to greater extent than heterologous ECM hydrogels, Lin et 
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al.114 found that a pepsin-digested extract of decellularized MSC sheets provided no additional 
benefit over type 1 collagen hydrogels; conversely, a urea-extracted fraction enhanced MSC 
attachment, spreading, proliferation, migration, and multi-lineage differentiation. Similarly, 
Zhang et al.113 and Yang et al.115 independently reported that urea-extracted fractions of 
decellularized ECM from diverse tissues were capable of promoting tissue-specific 
differentiation.   
In this study, soluble decellularized tendon and cartilage ECMs were prepared by pepsin 
digestion or urea extraction.  In confirming the superiority of urea-extracted over pepsin-digested 
solutions in terms of proliferation and tissue-specific differentiation of MSCs grown in 2-
dimensional (2D) cultures, the bioactivities of urea-extracted ECM solutions were further 
investigated across several three-dimensional (3D) conditions – pellet cultures, electrospun 
nanofibers, and photocrosslinked methacrylated gelatin (GelMA) hydrogels.  Supplementation of 
culture medium with TGF-β3 served as a positive control.  We hypothesized that urea-extracted 
ECM fractions would promote homologous differentiation regardless of the 3D condition, while 
the effect of TGF-β3 would be more strongly mediated by the microenvironment. 
2.2 METHODS  
2.2.1 Overview 
Tendon and hyaline cartilage were procured from bovine hindlimbs and subsequently 
decellularized and characterized.  Tendon and cartilage ECM were then solubilized through 
either pepsin digestion (tAP, cAP) or urea extraction (tECM, cECM) and their respective effects 
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on human MSC proliferation and gene expression were determined in 2D culture.  MSCs were 
cultured as pellets, seeded on aligned nanofibrous scaffolds, or encapsulated in GelMA 
hydrogels, and exposed to media supplemented with TGF-β3, urea-extracted tendon ECM 
(tECM), or urea-extracted cartilage ECM (cECM).  Assays for gene expression, histology, and 
biochemical composition were performed to assess tissue-specific bioactivities of the 
supplements.  Additionally, the effect of inhibiting endogenous TGF-β found in urea-extracted 
ECM fractions was explored in pellet cultures by inclusion of small molecule SB-431542. 
2.2.2 Decellularization of tendon and cartilage 
Patella tendon and articular cartilage were procured from hindlimbs of 6-8 week old cows 
(Research 87, Boylston, MA, USA) and stored at -20°C in a protease inhibitor solution 
composed of 1X phosphate-buffered saline (PBS, Gibco, Grand Island, NY, USA) supplemented 
with 5 mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, St. Louis, MO, USA) and 
0.5 mM phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich) until use.  Upon thawing, tissues 
were minced (8-27 mm3) and cryomilled (Spex Freezer Mill 8670, Metuchen, NJ, USA).  4 g of 
wet tissue powder was suspended in 40 mL of protease inhibitor solution containing 1% Triton 
X-100 (Sigma-Aldrich) and agitated for 24 hours at 4°C, followed by three washes for 30
minutes each in 1X PBS.  Tissue powders were subsequently exposed to 40 mL of Hanks 
Buffered Salt Solution (HBSS, ThermoFisher Scientific, Pittsburgh, PA, USA) supplemented 
with 200 U/mL DNase and 50 U/mL RNase (Worthington, Lakewood, NJ, USA) for 12 hours at 
room temperature.  Decellularized powders were then washed 6 times with 1X PBS and 
characterized for histological appearance and biochemical composition.  
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2.2.3 Solubilization of decellularized ECM 
Pepsin digestion. Decellularized tendon and cartilage ECM powders (30 mg/mL) were 
enzymatically digested in a solution of 1 mg/mL porcine pepsin (Sigma-Aldrich) in 0.01 N HCl 
for 48 hours at room temperature under continuous stirring.  If added as a medium supplement, 
digested tendon and cartilage ECM were neutralized by addition of one-tenth digest volume of 
0.1 N NaOH and one-ninth digest volume of 10X PBS while keeping the samples at 4°C.  
Samples were diluted with 1X PBS.  To form 3D hydrogels, pH neutralized digests were warmed 
to 37°C for 1 hour, as reported previously.104,150  
Urea extraction.  A water-soluble fraction of tendon and cartilage ECM was obtained 
through urea extraction, as previously described.115 Briefly, 4 g of wet decellularized ECM 
powder was agitated for 3 days at 4°C in 40 mL of 3 M urea dissolved in water.  The suspension 
was centrifuged for 20 minutes at 1500g and the supernatant was transferred to benzoylated 
tubing (Sigma-Aldrich) and dialyzed against ddH2O for 2 days at 4°C, changing the water every 
8 hours.  The dialyzed ECM extract was transferred to centrifugal filter tubes (3000 MWCO; 
EMD Millipore, Billerica, MA, USA) and spin-concentrated approximately 10-fold at 1500g for 
60 minutes.  The final ECM extract was filter-sterilized through a PVDF syringe filter unit (0.22 
µm; EMD Millipore).  The total protein concentration was determined by BCA assay 
(ThermoFisher Scientific) and aliquots of 1000 µg/ml were stored at -80°C until further use.  
Before use in experimental studies, aliquots prepared from three different batches were pooled. 
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2.2.4 SDS-PAGE and growth factory analysis of soluble ECM 
Samples of native tendon and cartilage ECM, and their corresponding urea-soluble and pepsin-
digested extracts were suspended in TM buffer (Total Protein Extraction Kit, EMD Millipore). 
30 µg total protein was mixed with LDS loading buffer and reducing agent (NuPAGE; Life 
Technologies, Carlsbad, CA, USA) and heated for 10 minutes at 70°C.  Protein was loaded into a 
pre-cast 10-well NuPAGE 4-12% Bis-tris Minigel (Life Technologies) and separated by 
electrophoresis in MOPS running buffer for 50 minute at constant 200V.  The gel was washed 
several times in water and photographed using a CCD camera gel imaging system (FOTODYNE, 
Hartland, WI, USA).   
Additionally, the growth factor contents of the soluble ECM preparations were 
determined using a Human Growth Factor Array (RayBiotech, Norcross, GA), according to the 
manufacturer’s instructions.   
2.2.5 MSC isolation 
Human MSCs were obtained as previously described,114 with Institutional Review Board 
approval (University of Washington and University of Pittsburgh). MSC populations isolated 
from individual patients were routinely validated as capable of osteogenic, adipogenic and 
chondrogenic differentiation (data not shown). All experiments were performed with passage 3 
(P3) MSCs. MSCs from 3 patients (56 year old male, 56 year old female, 59 year old male) were 
pooled for this study. 
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2.2.6 Bioactivity of soluble ECM in 2-dimensional cell culture 
To determine the effect of soluble ECM preparations on MSC morphology and metabolism, 1 x 
103 cells/cm2 were suspended in growth medium (DMEM, 10% FBS, 1% Anti-Anti; Life 
Technologies) and plated in 6-well culture plates.  One day following cell seeding, growth 
medium was replaced with serum-free medium (DMEM, 1% Anti-Anti, 1% Insulin-transferrin-
selenium [ITS]; Life Technologies) with or without additional supplementation.  There were six 
medium conditions – (1) serum-free control, (2) 10 ng/mL TGF-β3 (Peprotech, Rocky Hill, NJ, 
USA), (3) 50 µg/mL tAP, (4) 50 µg/mL tECM, (5) 50 µg/mL cAP, (6) 50 µg/mL cECM.  Media 
were changed every 2 days. On days 1, 3, and 7, an MTS assay (CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay; Promega, Madison, WI, USA) was performed according to 
manufacturer’s instructions. To determine the effects of soluble ECM on gene expression, 2 x 
104 cells/cm2 were plated in 6-well culture plates and cultured up to 7 days, as described above. 
On days 1, 3, and 7, cell lysates were collected for quantitative real-time polymerase chain 
reaction (qPCR, described below). As significant differences across treatment groups were only 
seen at day 3, expression levels were normalized against day 3 controls. 
2.2.7 Quantitative real-time polymerase chain reaction (qPCR) 
In 2D cultures, total RNA was isolated from cells using an RNeasy Plus Mini Kit (Qiagen, 
Valencia, CA, USA) and reverse transcribed into cDNA through use of SuperScript III first-
strand synthesis kit (ThermoFisher Scientific).  For 3D cultures, RNA isolation was preceded by 
homogenization of samples in Trizol (ThermoFisher Scientific). qPCR was performed using 
SYBR® Green master mix (Applied Biosystems, Foster City, CA, USA) on a StepOnePlus Real-
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Time PCR system (Applied Biosystems).  Relative expression of each target was calculated 
using the ∆∆CT method with the arithmetic average of GAPDH and r18S expression used as the 
endogenous reference. Primer sequences for gene targets are listed in Supplemental Table 1.  
2.2.8 Bioactivity of pepsin-digested ECM as 3-dimensional hydrogels 
To evaluate the bioactivity of pepsin-digested ECM as 3D hydrogels, 1.0 x 106 MSCs/mL were 
suspended in cold, pH-neutralized hydrogels (5 mg/mL), consisting of the following groups – (1) 
type 1 collagen (Control; PureCol® EZ Gel, Advanced Biomatrix, Carlsbad, CA, USA) (2) tAP, 
(3) cAP.  To induce thermogelation, MSC-seeded hydrogels were incubated for 1 hour at 37°C, 
after which reduced-serum medium (DMEM, 2% FBS, 1% Anti-Anti) was added.  Constructs 
were collected on day 7 for qPCR.   
2.2.9 Bioactivity of urea-extracted ECM in culture of MSC pellets 
 2.5 x 105 MSCs/mL in 200 µL chondrogenic medium (DMEM, 1% Anti-Anti, 10 µg/ml 
insulin, transferrin, selenium [ITS+], 0.1 µM dexamethasone, 40 µg/mL proline, 50 µg/mL 
ascorbate-2-phopshate) were distributed to conical 96-well plates and centrifuged for 10 minutes 
at 300g. Pellets were cultured for 21 days in one of four medium conditions – (1) Control, (2) 10 
ng/mL TGF-β3, (3) 50 µg/mL tECM, (4) 50 µg/mL cECM – with medium changes every 2 days.  
At day 21, pellets were collected for qPCR, histology, and biochemical analysis.  
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2.2.10 Effect of TGF-β inhibition on urea-extracted ECM bioactivity 
MSC pellets were cultured for up to 21 days in one of four conditions, as described in section 
2.3.9.  Small molecule SB-431542 (Sigma) was added at a final concentration of 10 µM 
approximately 1 hour prior to adding the appropriate culture supplement (i.e., 10 ng/mL TGF-β3, 
50 µg/mL tECM, 50 µg/mL cECM).  Media were changed every 2 days. qPCR, histology, and 
analysis of biochemical composition were performed on day 21.  As supplementation with SB-
431542 did not dramatically affect gene expression patterns compared to pellets cultured in 
control medium (i.e., without SB-431542), relative fold changes are shown normalized against 
the Control+SB-431542 medium condition for clarity. 
2.2.11 Histology and immunofluorescence 
All samples collected for histology (excluding electrospun nanofibers, as described in section 
2.3.12.) were fixed in 10% phosphate-buffered formalin, serially dehydrated, embedded in 
paraffin, and sectioned (6 µm thickness) with a microtome (Leica RM2255, Leica Biosystems, 
Buffalo Grove, IL, USA).  Samples were rehydrated and stained with hematoxylin & eosin 
(H&E, Sigma-Aldrich), Safranin O and Fast Green (Electron Microscopy Sciences, Hatfield, PA, 
USA) or 4’,6-diamidino-2-phenylindole, dilactate (DAPI, Life Technologies, Carlsbad, CA, 
USA).   
For samples undergoing immunofluorescent staining, antigen retrieval entailed 
incubation with Chondroitinase ABC (100 mU/mL) and Hyaluronidase (250 U/ml) suspended in 
0.02% BSA for 30 minutes at 37°.  Samples were incubated overnight at 4° with the following 
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primary antibodies – 1:400 Rabbit Anti-Collagen II (ab34712, Abcam, Cambridge, MA, USA), 
1:400 Mouse Anti-Collagen I (5D8-G9/Col1, ThermoScientific), or 1:400 Mouse Anti-Collagen 
X (ab49945, Abcam).  Samples were incubated in one of two secondary antibodies for 1 hour at 
room temperature – 1:500 AlexaFluor 488 goat anti-mouse or AlexaFluor 594 goat anti-rabbit 
(Invitrogen, ThermoFisher Scientific). 
Samples were photographed using an Olympus SZX16 stereomicroscope with white light 
(H&E, Safranin O) or fluorescent excitation at 405 nm (DAPI), 488 nm (green), or 594 nm (red) 
for immunofluorescence.   
2.2.12 Biochemical composition  
To determine the biochemical composition of tissues and 3D constructs, dry samples were 
digested overnight at 65°C at a concentration of 10 mg/mL in a digestion buffer (pH 6.0) 
containing 2% papain (v/v, from Papaya latex, Sigma-Aldrich), 0.1 M sodium acetate, 0.01 M 
cysteine HCl, and 0.05 M EDTA. Concentrated NaOH was subsequently added to the digestion 
solution to adjust the pH to 7.0. sGAG content was quantified with a Blyscan Assay according to 
the manufacturer’s instructions (Biocolor, Carrickfergus, UK). dsDNA content was determined 
using the Quant-iT Picogreen dsDNA assay (Invitrogen). Total collagen was determined using a 
modified hydroxyproline assay. Briefly, 200 μL of each sample was hydrolyzed with an equal 
volume of 4 N NaOH at 121°C for 75 min, neutralized with an equal volume of 4 N HCl, and 
then titrated to an approximate pH of 7.0. The resulting solution was combined with 1.2 mL 
chloramine-T (14.1 g/L) in buffer (50 g/L citric acid, 120 g/L sodium acetate trihydrate, 34 g/L 
NaOH, and 12.5 g/L acetic acid) and allowed to stand at room temperature for 30 min. The 
solution was then combined with 1.2 mL of 1.17 mM p-dimethylaminobenzaldehyde in 
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perchloric acid and placed in a 65°C water bath for 20 minutes.  200 µL of each sample was 
added to a clear 96-well plate, in duplicate, and absorbance at 550 nm was read. PureCol bovine 
collagen (3.2 mg/mL, Advanced Biomatrix) was serially diluted to provide a standard curve 
ranging from 0 to 1000 µg/ml.  
2.2.13 Bioactivity of ECM in culture of MSC-seeded aligned nanofibers 
Sheets of aligned nanofibers were fabricated from a solution of poly-ε-caprolactone (PCL, MW 
= 70k-90k, Sigma-Aldrich) prepared at 15% w/v in 1:1 (v/v) tetrahydrofuran (THF, Sigma-
Aldrich):dimethylformamide (DMF, ThermoFisher Scientific). Dissolved PCL was loaded into 
10 mL syringes and extruded through an 18-gauge blunt tip needle at 3.0 mL/h using a syringe 
pump (PY2 70,2209, Harvard Apparatus, Holliston, MA, USA).  The needle tip was placed 10 
cm from a custom-designed cylindrical mandrel, which rotated at a surface velocity of 10 m/sec.  
10-18 kV DC potential (Gamma High Voltage, Ormand Beach, FL, USA) was applied to the 
polymer solution while an 8 kV potential was applied to two aluminum shields placed 
perpendicular to the mandrel axis but parallel to the needle axis, narrowing the width of the 
aligned nanofibrous sheet collected on the grounded mandrel. 
6×104 MSCs/cm2 were seeded on PCL nanofibers and cultured for 14 days in serum-
reduced (2% FBS) culture medium supplemented with 50 µg/mL ascorbate-2-phosphate (Sigma-
Aldrich). There were four medium conditions –– (1) Control, (2) 10 ng/mL TGF-β3, (3) 50 
µg/mL tECM, (4) 50 µg/mL cECM – with medium changes every 2 days.  On day 14, constructs 
were collected for qPCR or immunofluorescent staining.  qPCR was performed as described 
above.  For immunofluorescent staining, constructs were fixed with 4% paraformaldehyde, and 
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blocked with 1% bovine serum albumin (BSA) and 22.5 mg/ml glycine in PBS-T. Constructs 
were exposed to goat anti-tenomodulin (Tnmd, 1:50, sc49325 Santa Cruz Biotechnologies, 
Dallas, TX, USA) overnight at 4°C. AlexaFluor 488 chicken anti-goat (Invitrogen, ThermoFisher 
Scientific) at a 1:500 dilution was used as the secondary antibody.  Constructs were 
counterstained with DAPI (Invitrogen) and cells were imaged using a confocal microscope 
(Olympus FluoView 1000).  
2.2.14 Bioactivity of cartilage ECM as in MSC-seeded GelMA hydrogels 
Methacrylated gelatin (GelMA) was synthesized by adapting a previously established 
protocol.134 Briefly, 15 g of gelatin (Type A, from porcine skin, Sigma-Aldrich) was dissolved in 
500 mL deionized H2O at 40°C, and then 15 mL of methacrylic anhydride (Sigma-Aldrich) was 
added dropwise under vigorous stirring. The mixture was placed at 37°C in an orbital shaker at 
150 rpm for 24 h. The resulting GelMA was dialyzed for 4 days against H2O at room 
temperature using 2000 NMWCO dialysis tubing (Sigma-Aldrich) to completely remove all low-
molecular-weight byproducts, with changes in H2O twice daily. After lyophilization, the product 
was stored at -20°C until future use.  Prior to use, GelMA was reconstituted at 10% (w/v) in 
HBSS.  0.25% v/v of visible light-sensitive photoinitiator lithium phenyl-2,4,6-
trimethylbenzoylphosphinate (LAP) was then dissolved by gentle shaking at room temperature.   
Photocrosslinking was induced by exposure to UV light (LED bulbs, 390-395 nm, 0.5 W) for 2 
minutes. 
MSCs were homogenously suspended in one of two hydrogels – (1) 10% w/v GelMA 
(Control) or (2) 10% w/v GelMA supplemented with 500 µg/mL cECM (cECM) – at a 
concentration of 20 x 106 cells/mL.  Before gelation, MSC-seeded hydrogels (~50 µL) were 
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distributed to silicone molds measuring 5 mm diameter x 2 mm depth.  To induce photogelation, 
hydrogels were exposed to 2 minutes of visible light (450-490 nm) (Supplemental Figure 1).  
MSC-seeded hydrogels were then removed from silicone molds and transferred to 6 well plates 
previously coated with silicone (Sigmacote, Sigma-Aldrich) to prevent cell migration and 
adhesion onto the plastic surface.  Constructs were cultured up to 21 days in chondrogenic 
medium (DMEM, 1% Anti-Anti, 10 µg/ml insulin, transferrin, selenium [ITS+], 0.1 µM 
dexamethasone, 40 µg/mL proline, 50 µg/mL ascorbate-2-phopshate) with or without additional 
10 ng/mL TGF-β3 (Peprotech) supplementation.  Medium was changed every 2 days.  
2.2.15 Statistics 
Comparisons across multiple conditions or time points were made using a one-way or two-way 
analysis of variance (ANOVA) with Tukey post-hoc testing for multiple comparisons.  When 
comparing two conditions, a Student’s t-test was performed.  Data are presented as mean ± 
standard deviation.  Experiments were performed with biological triplicates over at least three 
independent trials.  Sample sizes are indicated in figure legends.  Statistical significance was 
considered p < 0.05. 
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2.3 RESULTS 
2.3.1 Characterization of tendon- and cartilage-derived ECMs 
The decellularization protocol successfully reduced cellular content from both tendon and 
cartilage, as evidenced by the absence of nuclei on both H&E- and DAPI-stained sections 
(Figure 7A-H), as well as a significant reduction in dsDNA content (Figure 7I).  The total 
collagen contents of native and decellularized tendon were equivalent, while decellularized 
cartilage exhibited a significant increase in collagen content with a corresponding loss in sGAG 
content (Figure 7J-K).  The majority of decellularized tissue powder was insoluble in urea 
(Figure 7L) but was homogenously digested by the acid-pepsin solution (Figure 7M).  As a 
result, urea-extracted tendon ECM (tECM) and cartilage ECM (cECM) were enriched for low- to 
moderate-weight proteins, with faint bands corresponding to collagen.  Conversely, the pepsin-
digested tendon (tAP) and cartilage (cAP) were principally composed of collagen types 1 and 2, 
respectively, with faint bands found in the low- to moderate-weight regions (Figure 7N,O).  The 
prominent streak in the well of native cartilage is an artifact attributable to the high proteoglycan 
content (Figure 7O).  tECM and cECM possessed a higher growth factor content than their 
pepsin-digested counterparts, with notable differences in basic fibroblast growth factor (bFGF) 
and TGF-β1 (Supplemental Table 2). 
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Figure 7. Characterization of soluble extracellular matrices. (A-D) Prior to decellularization, 
nuclei are clearly present in native tendon and cartilage tissues, as shown through H&E and 
DAPI staining.  (E-H) Following decellularization, no nuclei are visible.  (I) dsDNA contents 
were significantly reduced in decellularized tissues compared to native tissues, p < 0.001, n=8.  
(J) Collagen content in native and decellularized tendon was equivalent, but was increased in 
decellularized cartilage vs. native cartilage, p < 0.05, n=8.  (K) sGAG content was higher in 
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cartilage tissues than tendon tissues, regardless of decellularization step (p <0.05) but 
decellularized cartilage contained significantly less sGAG than native cartilage (p <0.001, n=8). 
(L) Urea extraction yielded an insoluble and soluble fraction.  The soluble supernatant (yellow 
line) was collected.  (M) Pepsin digestion yielded a homogeneous slurry.  (N, O) SDS-PAGE 
gels of tendon (N) and cartilage (O) tissues at different stages of decellularization and 
solubilization.   
2.3.2 The effect of soluble ECMs on human MSCs in 2D culture 
Human MSCs were grown on 2D culture plastic in one of six medium conditions (Figure 8A).  
Pepsin-digested and urea-extracted ECM supplementation enhanced cell proliferation, with the 
urea-extracted groups showing the greatest effect by day 7 (Figure 8B).  Only the urea-extracted 
ECMs upregulated tissue-specific transcription factors; tECM preferentially enhanced Scx 
expression while cECM upregulated Sox9 expression (Figure 8C).  No soluble ECM preparation 
affected expression of osteogenic marker, Runx2.  Collagen type 2 (Col2) and aggrecan (Acan) 
expression was not detectable, while collagen type 1 (Col1) was only significantly upregulated 
by TGF-β3, which also greatly increased Scx expression (Figure 8C).  MSCs grown in tECM-
supplemented medium possessed a spindle-shaped morphology, while cECM and, to a lesser 
extent, TGF-β3 supplementation produced a cobblestone morphology (Figure 8D). 
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Figure 8. The effect of soluble ECMs on human MSCs in 2D culture. (A) MSCs were 
cultured up to 7 days on tissue culture plastic in one of six medium conditions. (B) MTS assay 
showed that all ECM groups enhanced cell metabolism (proliferation), but urea-extracted 
fractions were the most mitogenic by day 7. (C) Gene expression analysis on day 3 suggested 
tissue-specific bioactivity of urea-extracted ECM fractions (p < 0.05, n=9). (D) Phase contrast 
microscopy showed spindle-shaped cells in the tECM group but cobblestone morphology with 
TGF-β and cECM supplementation. 
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2.3.3 The effect of soluble ECMs on MSC pellets  
Total and relative sGAG contents were increased in pellets cultured in supplemented medium 
(Figure 9B).  TGF-β3 and cECM supplementation increased total sGAG to a similar extent, but 
cECM was superior when sGAG content was normalized by dsDNA content (Figure 9B).  In 
terms of gene expression (Figure 9C), TGF-β3 preferentially promoted a chondrogenic 
phenotype as shown by increased expression of Sox9, Acan, and Col2.  tECM promoted a 
tenogenic phenotype with robust upregulation of Scx, Mkx, Col3, and Col1, with more modest 
effects on chondrogenic and osteogenic markers.  Similarly, cECM had a negligible or inhibitory 
effect on tenogenic markers but promoted chondrogenesis to an equivalent or greater degree than 
TGF-β3. However, cECM also upregulated osteogenic markers most strongly, as seen in 
expression patterns of Col10 (hypertrophic marker), Runx2, Alp, and Ocn (Figure 9C).  
Histological analysis of pellets showed a pattern that was consistent with assays for biochemical 
composition and gene expression.  Namely, TGF-β3 and cECM enhanced proteoglycan and Col2 
deposition while tECM pellets showed the greatest Col1 staining intensity (Figure 10). 
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Figure 9. The effect of soluble ECMs on MSC pellet composition and gene expression. (A) 
MSC pellets were cultured in one of four medium conditions for 21 days.  (B) Biochemical 
composition of pellets reveals anabolic and mitogenic effects for all supplements; cECM 
promoted the greatest relative sGAG production (p < 0.05, n=9).  (C) Gene expression analysis 
on day 21 shows chondrogenic effects of TGF-β, tenogenic effects of tECM, and chondrogenic 
and osteogenic effects of cECM (p < 0.05, n=9). 
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Figure 10. The effect of soluble ECMs on MSC pellet protein deposition. TGF-β and cECM 
promoted deposition of proteoglycan, Col2, and Col10, while tECM enhanced Col1 synthesis.  
Proteoglycan (Safranin O) = red, Collagen 2 = red, Collagen 1 = green, Collagen 10 = green, 
nuclei = blue 
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2.3.4 The effect of TGF-β inhibition on soluble ECM bioactivity 
The effects of endogenous TGF-β in tECM and cECM were blocked by type 1 TGF-β receptor 
antagonist SB-431542,151 which was added at 10 µM to pellet culture media (Figure 11A). TGF-
β inhibition significantly reduced the anabolic effects of TGF-β and cECM on pellets, as 
evidenced by the loss of proteoglycan staining (Figure 11B) and sGAG content (Figure 11C, 
Supplemental Figure 2).  In analysis of gene expression (Figure 11D), SB-431542 eliminated 
the tenogenic effect of tECM and the chondrogenic effect of TGF-β.  Interestingly, cECM 
supplementation still promoted significant increases in Sox9, Acan, and Col2 expression despite 
treatment with SB-431542 (Figure 11D), although these increases were far weaker than pellets 
treated with cECM in the absence of SB-431542 (Figure 9C).  ECM-mediated upregulation of 
osteogenic markers alkaline phosphatase (Alp) and osteocalcin (Ocn) also persisted in the 
presence of TGF-β inhibition. 
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Figure 11. The effect of TGF-beta inhibition on soluble ECM bioactivity. (A) Medium 
conditions for pellet cultures were further supplemented with 10 µM SB-431542. (B) Safranin O 
Staining. (C) Normalized sGAG content shows blunted anabolic effects of medium supplements 
(p < 0.05, n=9); dotted line indicates sGAG/dsDNA content of control medium (without SB-
431542).  (D) Gene expression analysis shows complete inhibition of exogenous TGF-β and 
blunted tissue-specific bioactivity of ECM supplements (p < 0.05, n=9). 
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2.3.5 The effect of soluble ECMs on MSCs seeded on aligned nanofibers 
MSCs seeded on aligned PCL nanofibers (Figure 12A) became elongated in the direction of the 
fibers (data not shown). TGF-β3 supplementation upregulated both tenogenic (Scx, Tnc, Col3, 
Col1) and chondrogenic (Sox9, Col10) markers, while tECM supplementation enhanced 
expression of tenogenic markers only (Figure 12B).  cECM modestly increased tenogenic 
markers (Scx, Tnc, Col3) but upregulated chondrogenic markers (Sox9, Col2, Col10) to an 
equivalent or greater extent than TGF-β3. cECM also upregulated Runx2.  All supplements 
decreased gene expression of cartilage proteoglycan Acan and bone protein osteocalcin (Ocn).  
Paralleling the expression pattern of Scx, an upstream driver of tenodmodulin (Tnmd)12, confocal 
microscopy revealed the greatest staining intensity for Tnmd in the TGF-β3 group. However, 
tECM enhanced Tnmd translation to a greater extent than cECM (Figure 12C). 
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Figure 12. The effect of soluble ECMs on MSCs on aligned nanofibers. (A) MSCs were 
cultured on aligned PCL nanofibers in one of four medium conditions.  (B) Gene expression 
analysis on day 14 showed tenogenic and chondrogenic effects due to TGF-β supplementation. 
tECM supplementation promoted a tenogenic phenotype while cECM upregulated chondrogenic 
markers and Runx2.  Both TGF-β and cECM increased expression of hypertrophic marker, 
Col10 (p <0.05, n=9). (C) Immunofluorescent staining of tenomodulin shows increasing 
intensity in the following order: Control < cECM < tECM < TGF-β; Tnmd = green, nuclei = 
blue. 
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2.3.6 The independent and synergistic effects of cECM and TGF-β on chondrogenesis of 
MSCs seeded in 3D GelMA hydrogels 
MSCs were seeded in photocurable GelMA hydrogels and cultured in chondrogenic medium 
(with or without TGF-β supplementation) for up to 21 days (Figure 13A).  On day 7, the 
inclusion of cECM within the hydrogels had independently upregulated chondrogenic markers 
Sox9, Acan, and Col2, as well as the ratio of Col2:Col1, despite a more modest increase in Col1 
(Figure 13B).  Runx2 expression was also upregulated by cECM on day 7, but was equivalent to 
controls (and returned to baseline) by day 21.  Supplementation of culture medium with TGF-β 
dramatically enhanced the expression of chondrogenic markers, compared to controls, on days 7 
and 21.  The effect was further enhanced when cECM was mixed with the GelMA hydrogel, 
suggesting a synergistic effect between the cECM and TGF-β (Figure 13B).  This synergistic 
effect was also confirmed when analyzing the biochemical composition of MSC-seeded 
hydrogels (Figure 13C).  Importantly, acellular cECM-containing GelMA hydrogels had 
negligible sGAG content (data not shown), suggesting that the observed group differences are 
attributable to the effects of cECM on MSCs rather than sGAG contained within cECM solution. 
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Figure 13. The effects of cECM and TGF-beta on chondrogenesis of MSC-GelMA 
hydrogels. (A) MSC-seeded GelMA hydrogels, with or without cECM enhancement, were 
cultured in chondrogenic medium, with or without TGF-β supplementation, for up to 21 days.  
(B) Gene expression analysis shows independent and synergistic effects of cECM and TGF-β (p 
< 0.05, n=9).  (C) Biochemical composition shows synergistic effect of cECM and TGF-β in 
enhancing absolute and normalized sGAG production (p < 0.05, n=9). 
 53 
2.4 DISCUSSION 
Given the conservation of ECM proteins across species, the utility of decellularized tissues as 
biomaterials capable of promoting tissue-specific cell phenotypes is theoretically and empirically 
supported.7,152 Nevertheless, there is an inherent trade-off between tissue processing and 
retention of bioactive cues.6 While sufficient decellularization is required to mitigate an adverse 
immune response to the implanted scaffold,153 it is uncertain which elements of the ECM must 
be preserved to retain homologous bioactivity.  Pepsin digestion of decellularized ECMs yields 
viscous slurries capable of undergoing thermoresponsive gelation when pH balanced,104,154 
providing an attractive biomaterial for minimally invasive cell delivery to irregularly shaped 
defects.  On the other hand, characterization of pepsin-digested ECMs is seldom performed.  Our 
group114 and others112,149 have recently reported that pepsin solubilization produces digests 
composed principally of structural ECM proteins, especially collagen.  A similar finding was 
seen in this study.  Additionally, the tissue-specific bioactivity of pepsin-digested tendon105,106 
and cartilage ECM84,108 remains relatively unexplored. Pati et al.107 reported an ~ 1.5-fold 
increase in Sox9 and Col2 expression when human MSCs were seeded in cAP hydrogels, as 
compared to collagen 1 hydrogels.  Conversely, two related studies110,111 found a negligible 
effect of pepsin-digested cartilage ECM, compared to controls, in enhancing chondrogenesis. A 
similar (null) effect was found in this study when pepsin-digested ECMs were added as a culture 
supplement (Figure 8) or seeded with MSCs as 3D thermoresponsive hydrogels (Supplemental 
Figure 3).   
In contrast, we previously found that urea-extracted tendon ECM (tECM) upregulated 
expression of tenogenic markers, with concurrent downregulation of osteogenic markers, in 
MSCs cultured in a hydrogel under static uniaxial tension.115 Zhang et al.113 reported similar 
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findings when coating tissue culture dishes with urea-extracted ECM derived from skin, skeletal 
muscle, and liver.  Building on these findings, this study found that urea-extracted tECM and 
cECM upregulated homologous transcription factors (i.e., Scx and Sox9, respectively) in MSCs 
grown on 2D plastic, while exogenous TGF-β3 preferentially upregulated Scx alone. 
Furthermore, tECM and cECM enhanced cell proliferation to a greater extent than TGF-β3, tAP, 
or cAP, and mediated differences in cell morphology.  However, these effects were not sustained 
beyond 7 days, likely attributable to the stress of sustained serum-starvation coupled with the 
non-physiologic biophysical microenvironment (i.e., 2D plastic).  Therefore, we explored the 
tissue-specific bioactivity of tECM and cECM in two different 3D microenvironments – cell 
pellets and aligned electrospun nanofibers. 
Pellet cultures were employed as an in vitro assay to replicate the early condensation, and 
subsequent tenogenesis and chondrogenesis, of mesenchymal cells in limb formation.  In this 
context, TGF-β3 preferentially promoted chondrogenesis, while tECM and cECM promoted 
homologous gene expression (i.e., tenogenesis and chondrogenesis, respectively).  TGF-β is 
essential for mediating both tenogenesis and chondrogenesis in vivo,146,155 yet its in vitro effect is 
variable, depending on other microenvironmental cues.  For instance, Lorda-Diez et al.156,157 
identified several downstream regulators of TGF-β signaling that mediated either fibrogenic or 
chondrogenic differentiation.  Interestingly, in this study, inhibition of TGF-β type 1 activin 
receptor-like kinase receptors ALK4, ALK5, and ALK7 by SB431542151 abolished the tissue-
specific bioactivity of tECM and cECM, suggesting that TGF-β signaling is necessary, but not 
sufficient, to explain their tissue-specific effects.  It is always noteworthy that the concentrations 
of endogenous TGF-β found in tECM and cECM were in the pg/mL range, yet supplementation 
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with these extracts promoted homologous bioactive effects equaling or exceeding those produced 
by 10 ng/ml exogenous TGF-β. 
A growth factor array further revealed differences in composition between tECM and 
cECM; it is possible that the greater concentrations of bFGF, BMP-5, and BMP-7, found in 
cECM mediated the cartilage-specific effects.  But given their role in bone formation,158 the 
additional BMPs found in cECM may also have contributed to the noted upregulation of 
hypertrophic and osteogenic markers seen in this study, although TGF-β alone induced some 
degree of hypertrophy in pellet cultures.  The finding of cartilage ECM-induced hypertrophy has 
also been recently reported in similar studies.159,160 Indeed, the stability of the chondrogenic 
phenotype remains a persistent challenge in cartilage tissue engineering.3 It is possible that the 
use of cECM derived from adult animals could promote chondrogenic differentiation with less 
hypertrophy, as the delineation between articular cartilage and subchondral bone (with obvious 
vasculature) is apparent (Supplemental Figure 4), allowing for the isolation of cartilage ECM 
alone. As shown in the growth factor array (Supplemental Table 2), cECM from 2-3 year old 
animals contains a lower concentration of growth factors than cECM from 6-8 week old animals 
(as used in this study), but also greatly reduced levels of BMPs. Clearly, further elucidation of 
soluble ECM composition, and the interactions among these elements, will be necessary to 
expand on the findings obtained herein, thereby furthering our understanding of cell-matrix 
interactions.  
However, based upon these promising results that suggested tissue-specific bioactivity of 
urea-extracted ECMs, we sought to explore if additive or synergistic effects were possible when 
combining these soluble extracts with biomimetic scaffolds. Electrospun nanofibers mimic the 
structural proteins of musculoskeletal tissue ECM (e.g., collagen) and are capable of directing 
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cell behavior.161 In particular, aligned nanofibers, reminiscent of the aligned collagen 1 fibrils of 
native tendon, have been shown to promote tenogenic differentiation of seeded stem 
cells.121,124,125 Furthermore, Leung et al.127 reported that supplementation with TGF-β3 further 
enhanced tenogenesis in MSCs seeded on aligned chitosan-PCL nanofibers while Kishore et 
al.129 found no additional effect of BMP-12 supplementation with MSCs seeded on 
electrochemically aligned collagen threads.  Similarly, nonaligned PCL nanofibers coated with 
pulverized tendon ECM showed little benefit over nanofibers alone in promoting a tenogenic 
phenotype of seeded MSCs.103 These conflicting results suggest a complex interaction between 
biophysical and biochemical cues in directing cell differentiation.  Nevertheless, in this study, 
tECM supplementation further upregulated expression of tenogenic markers, with negligible or 
inhibitory effects on chondrogenic and osteogenic expression in MSCs seeded on aligned 
nanofibers.  cECM affected expression of chondrogenic markers to a similar extent as TGF-β3, 
with a relatively diminished effect on tenogenic markers.  Of note, Scx is known to cooperatively 
regulate Sox9 and Col2 expression in the context of chondrogenesis,162 despite its common 
categorization as a tendon-specific marker,11 perhaps explaining the small but significant 
upregulation of Scx mediated by cECM.  In contrast, TGF-β3 upregulated markers of both 
tenogenesis and chondrogenesis.   
Given the tissue-specific bioactivity of soluble ECMs exerted on MSC-seeded 
nanofibers, we sought to explore the possible benefit of including cECM within a 
photocrosslinkable hydrogel, a biomimetic scaffold often used for cartilage tissue engineering.  
Of additional consideration, the inclusion of cECM within the hydrogel itself, as opposed to the 
culture medium, makes its application more clinically relevant.  The provision of cartilage ECM 
structural proteins such as collagen type VI,163 collagen type II, and proteoglycans,164,165 within 
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MSC-seeded hydrogels has been found to enhance chondrogenic differentiation.  Similarly, 
Almeida et al.99,101 reported similar improvements when using decellularized cartilage ECM 
particles.  In this study, cECM was mixed with photocrosslinkable GelMA hydrogels, a 
biomaterial which we previously found to support robust chondrogenesis.134 cECM 
independently enhanced chondrogenesis at day 7, but the chondroinductive effect decreased by 
day 21.  Rather, medium supplementation with TGF-β was required for sustained upregulation of 
chondrogenic markers, with a corresponding deposition of cartilage ECM proteins; this finding 
agrees with related work.99-101 Despite the apparent necessity of exogenous TGF-β for robust 
cartilage formation, cECM within the hydrogel interacted synergistically with the supplemented 
TGF-β, as demonstrated by the greatest increases in chondrogenic gene expression and sGAG 
deposition seen in this group.  Given these results, we are now developing cECM-enhanced 
hydrogels with controlled release of encapsulated TGF-β, potentially obviating the need for 
medium supplementation and improving the translational applicability of this approach. Taken 
together with the results of MSC-seeded nanofibers, these findings support the tissue-specific 
bioactivity of urea-extracted ECMs when cells are seeded on biomimetic surfaces.  The results 
parallel those of Sun et al.,166 who reported increased osteogenesis when gelatin nanofibers were 
enhanced with noncollagenous proteins extracted from bone using a similar method to this study. 
Although this study found that urea-extracted ECM, rather than pepsin-digested ECM, is 
capable of promoting tissue-specific cell phenotypes across multiple culture conditions, we did 
not explore the many other benefits reported for pepsin-solubilized ECM.  In particular, pepsin 
ECM digests have been found to enhance in vitro cell migration,150 proliferation,167 and 
macrophage polarization,168 effects mediated by tissue source,169 animal age,170 and fraction.171  
In vivo, ECM-mediated effects on macrophage polarization, and the broader inflammatory 
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response, at least partially explain the benefit of ECM in promoting constructive remodeling 
(i.e., improved healing).172,173 To what extent in vitro assays for tissue-specific differentiation are 
predictive of enhanced in vivo healing remains unknown.  For instance, Keane et al.150 and Wolf 
et al.154 found that ECM hydrogels derived from esophagus and skeletal muscle, respectively, 
promoted tissue-specific differentiation of cells in vitro, but their effects in vivo were not 
superior to ECM hydrogels derived from heterologous tissues.  The effects of urea-extracted 
ECM fractions on macrophage polarization and in vivo healing were beyond the scope of the 
present investigation, but certainly worthy of future inquiry.  Indeed, it is self-evident that 
successful regeneration of musculoskeletal tissues will require a greater understanding of the 
intersection of biomimetic biomaterials that are capable of guiding tissue-specific cell 
phenotypes, with the resulting inflammatory response elicited when such constructs are 
implanted in vivo. 
2.5 CONCLUSIONS 
In this chapter, decellularized tendon and cartilage ECMs were solubilized either by pepsin 
digestion or urea extraction.  The effects of these preparations on human MSC behavior were 
evaluated in 2D and 3D cultures.  Pepsin-digested tendon and cartilage ECMs did not promote 
tissue-specific differentiation, as compared to controls, while urea-extracted fractions were 
mitogenic and upregulated homologous cell phenotypes.  When MSCs were cultured as pellets, 
inhibition of endogenous TGF-β by small molecule SB431542 largely negated the tissue-specific 
inductivity of urea-extracted ECMs, suggesting that endogenous TGF-β is necessary, but not 
sufficient, to explain the homologous bioactivity of tECM and cECM.   When added as a 
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component of a photocurable GelMA hydrogels, cECM independently upregulated early 
chondrogenesis of encapsulated MSCs, and synergistically enhanced chondrogenesis when 
exogenous TGF-β was added as a medium supplement.  Therefore, urea-extracted ECM fractions 
may be a promising biomaterial, which when combined with tunable scaffolds, can guide tissue-
specific cell differentiation.  However, our results, and those of others,99-101,110,159,174 suggest that 
robust neotissue formation likely requires supplementation with exogenous growth factors (e.g., 
TGF-β).  Building on the finding of synergism between cECM and TGF-β in inducing 
chondrogenesis in MSC-seeded GelMA hydrogels, we explored similar effects for tendon tissue 
engineering, as described in Chapter 3. 
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3.0  TENDON TISSUE ENGINEERING – COMBINING A BIOMIMETIC 
SCAFFOLD WITH SOLUBLE TENDON EXTRACELLULAR MATRIX AND TGF-β 
As shown in the previous chapter, MSCs cultured on aligned PCL nanofibers further upregulated 
tenogenic markers when the medium was supplemented with urea-extracted tECM.  In a 
subsequent experiment, MSC-seeded GelMA hydrogels demonstrated independent and 
synergistic enhancement of chondrogenesis when supplemented with cECM (in the hydrogel) 
and/or TGF-β3 (in the culture medium).   In the following chapter, we explore the possible 
synergism between tECM and TGF-β3 as promoters of tenogenic differentiation of MSCs grown 
on both 2D plastic and aligned fibrous scaffolds. As native tendon tissue is principally composed 
of type 1 collagen, this specific protein was included as a distinct experimental group to discern 
the bioactivity of collagen 1 (of tendon ECM) compared to that of the diverse protein 
composition found in urea-extracted tECM. Of clinical relevance, the MSCs used herein were 
derived from human adipose tissue rather than bone marrow, as the former is abundant, contains 
a higher proportion of MSCs, and causes minimal donor site morbidity.   
 
The following section contains material from the accepted publication: 
 Yang G, Rothrauff BB, Lin H, Yu S, Tuan RS. 2016. Tendon-Derived Extracellular 
Matrix Enhances TGF-β3 Induced Tenogenic Differentiation of Human Adipose-Derived Stem 
Cells.  Tissue Engineering Part A. [Accepted] 
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3.1 INTRODUCTION 
Tendon injuries occur frequently in sports and daily activities due to excessive load or overuse. 
Tendinopathies and tendon tears account for over 30% of all musculoskeletal consultations.175 
Unfortunately, the natural healing process of tendons is slow and insufficient, resulting in 
fibrotic scar formation and inferior mechanical strength at the injured sites.141 Current clinical 
outcomes of tendon repair remain unsatisfactory due to limitations including donor site 
morbidity, risk of injury recurrence, and limited long-term functional recovery.176-178 Therefore, 
tissue engineering approaches, which use a combination of cells, scaffolds, and bioactive 
molecules, are gaining increasing research interest as a promising alternative strategy to treat 
tendon injuries.    
The use of adult mesenchymal stem cells (MSCs) as the cellular component for tendon 
tissue engineering has been increasingly explored in recent years.179-181 Compared with other cell 
sources, adipose-derived mesenchymal stem cells (ASCs) are abundant and can be isolated by 
minimally invasive approaches.182,183 Although a variety of growth factors are able to induce 
expression of tenogenic markers in ASCs, no single growth factor has been found to exclusively 
promote tenogenic differentiation. For instance, in addition to its tenogenic effect,184,185 growth 
differentiation factor 5 (GDF-5) is also capable of stimulating ASC differentiation towards other 
mesenchymal lineages, such as osteogenesis186,187 and chondrogenesis.188 Likewise, transforming 
growth factor-β1 (TGF-β1) exhibits both tenogenic and chondrogenic effect for ASCs.189,190 
Rather, the evolving microenvironment produced by progenitor cells plays an important role in 
mediating cell responses to growth factors, which induce proliferation and tissue-specific 
differentiation during development and tissue repair.191-193 However, there is still limited 
 62 
understanding regarding how the biochemical and biophysical cues of the tendon 
microenvironment promote a tendon-specific cell phenotype. 
Studies in tendon development have revealed the complexity of tendon differentiation. As 
shown across several animal models, members of the TGF-β superfamily are actively involved in 
tendon development and healing in a spatiotemporally specific manner. For example, mouse 
patellar tendon cells were found to respond to TGF-β signaling at developmental stages starting 
at gestation day 17.5 and ending at postnatal day 14.194 Consistent with this finding, micromass 
culture of chick embryonic limb bud mesodermal cells with TGF-β demonstrated significant up-
regulation of tendon markers, scleraxis (SCX) and tenomodulin (TNMD), with concurrent 
reduction in cartilage markers.195 Conversely, disruption of TGF-β signaling resulted in the loss 
of most tendons and ligaments in a SCX-GFP mouse model.196 When injured, high levels of 
TGF-β expression and activity were also seen throughout the healing period.197-199   
Concurrently, recent research has illustrated the pivotal role of the extracellular matrix 
(ECM) in tendon differentiation.200,201 ECM is composed of the structural and signal molecules 
secreted by the resident cells of each tissue. While the ECM of most tissues share highly 
conserved structural proteins (e.g., collagen, proteoglycans), it is the unique biophysical 
arrangement of these proteins, and the highly orchestrated deposition and presentation of soluble 
cues that serve to promote and maintain a particular cell phenotype.202,203 Tendon is rich in ECM 
components, and many of the tendon ECM proteins have been found to play important roles in 
tendon differentiation and organization.204-206 As proof, tendon-derived stem/progenitor cells 
(TSPCs) seeded on decellularized tendon/ligament ECM demonstrated improved proliferation 
and tendon cell phenotype.207 Taken together, it is reasonable to assume that the presence of 
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native tendon ECM may be beneficial to TGF-β induced tenogenic differentiation of MSCs for 
tendon repair.  
In addition to biochemical cues, scaffolds are also utilized in tendon tissue engineering to 
provide mechanical support as well as topographical cues that mimic the architecture of native 
tendon. Because tendon is primarily composed of aligned collagen fibers, scaffold anisotropy is 
an important topographical characteristic to consider in tendon tissue engineering. For instance, 
human tendon fibroblasts seeded on aligned microfibrous scaffolds exhibited increased 
expression of tendon phenotype markers.123 In this study, we have therefore prepared and 
employed aligned poly-ε-caprolactone (PCL) scaffolds to partially reproduce the biophysical 
features of native tendon ECM. 
The objective of this study was to investigate the effect of native tendon ECM 
components and TGF-β on the tenogenesis of human ASCs (hASC). A soluble extract of 
decellularized tendon ECM (tECM) was prepared as described previously.115 The individual and 
combined effects of tECM and TGF-β3 on hASC behavior, including proliferation and 
differentiation, were analyzed by using tECM as a medium supplement for ASCs cultured with 
or without TGF-β3 for up to 2 weeks on 2D tissue culture plastic or aligned PCL scaffolds. We 
hypothesized that tECM is able to enhance the proliferation and TGF-β3-induced tenogenesis of 
ASCs in vitro, and that tECM modulates matrix deposition and organization of ASCs on 
scaffolds.     
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3.2 MATERIALS AND METHODS 
3.2.1 Cell isolation and culture 
hASCs were obtained from lipoaspirates of two donors (34 years old male and 38 years old 
female) using an automated cell isolation system (Tissue Genesis Inc.), with University of 
Pittsburgh Institutional Review Board approval. Isolated hASCs were cultured in growth 
medium (GM) consisting of DMEM-high glucose (Gibco), 10% fetal bovine serum (FBS), and 
penicillin/streptomycin (P/S). hASCs between passage 2 and 4 (P2-P4) were used for 
experiments.  
3.2.2 Colony forming unit-fibroblast assay 
The colony forming unit-fibroblast (CFU-F) assay was performed using an established method 
described elsewhere with culture time extending up to 14 days.208 hASCs from each donor at P2 
were plated separately in 100 mm dishes (Falcon) in triplicate at densities of 100 cells per dish 
and cultured in GM. The cultures were stained with 0.5% crystal violet solution in methanol and 
visible colonies were scored.  
3.2.3 Flow cytometry 
hASCs at P2 were detached by trypsin-EDTA and incubated with propidium iodide (PI) and PE- 
or FITC-conjugated mouse (IgG1, κ) anti-human antibodies for 30 min at 4 C°. Antibodies 
include mouse anti-human CD31, CD34, CD44, CD45, CD73, CD90, CD105 (BD Biosciences). 
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Dead cells were excluded by positive PI staining. PE- or FITC-conjugated isotype-matched IgGs 
(BD Biosciences) were used as controls. After washing, the cells were sorted using the 
FACSAria II SORP flow cytometer (BD Biosciences), and data analyzed with DiVa v6 software.  
3.2.4 Preparation of tendon ECM 
A soluble fraction of tendon ECM (tECM) was prepared using our previously reported 
protocol.115 The proximal part of superficial digital flexor tendons was harvested from hind legs 
of 2-3 months old calves purchased from a commercial abattoir (Research 87 Inc.), pulverized, 
and decellularized by 1% Triton X-100 (Sigma-Aldrich). After nuclease treatment (200 U/ml 
DNase, Worthington), the acellular tissue was extracted in 3 M urea (Sigma-Aldrich) for 3 days. 
Urea was removed by dialysis in 3,500 MWCO cassettes (Thermo Scientific) against water for 2 
days, and then the tECM extract was spin-concentrated, sterilized using 0.22 µm PVDF syringe 
filter units (Millipore), and stored as 1 mg/ml stock at -20 °C until use. 
3.2.5 Preparation of scaffold 
Aligned microfibers were fabricated by electrospinning. A solution of PCL (MW = 70k-90k, 
Sigma-Aldrich) prepared at 18% w/v in 1:1 (v/v) dimethylformamide (DMF) and 
tetrahydrofuran (THF) (Fisher Scientific) was loaded into a 10 mL syringe and extruded at 2 
mL/h through a 22-gauge blunt-tip needle using a syringe pump (PY2 70-2209, Harvard 
Apparatus). A 10 kV DC potential (Gamma High Voltage) was applied to create an electrostatic 
field with a distance of 15 cm between the needle tip and a custom designed rotating mandrel. 
Electrospinning was performed for 2 hours per scaffold to form the scaffold sheet, which was 
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trimmed to 4 cm in width and dried in vacuum overnight to remove residual organic solvent. 
Scaffolds were cut into 20 mm x 5 mm rectangular pieces, hydrated and sterilized in 75% 
ethanol, and then soaked in GM overnight. The scaffolds were secured to the bottom of culture 
wells in customized incubators for cell seeding. 
3.2.6 Scaffold characterization 
Both aligned and non-aligned scaffolds were dried in vacuum, mounted on aluminum stubs, 
sputter-coated with 3.5 nm gold, and examined by a scanning electron microscope (SEM, field 
emission, JEOL JSM6335F) operated at 3 kV accelerating voltage and 8 mm working distance. 
The external surface of the central part of the constructs was selected for imaging. Fiber diameter 
and degree of alignment was quantified from the SEM images (n=4/group). Briefly, the 
diameters of 50 randomly selected fibers in each image were measured by ImageJ, and average 
fiber diameter calculated. The angle between fiber and horizontal orientation was measured by 
ImageJ (50 fibers counted in each image). The thicknesses of the scaffolds were measured by 
digital calipers (n=30).  
3.2.7 Differentiation of hASCs 
Differentiation along mesenchymal lineages, including osteogenesis, adipogenesis and 
chondrogenesis, was performed to assess the multipotency of the isolated hASCs using an 
established protocol with slight modifications.208 Briefly, 10 ng/ml bone morphogenetic protein 6 
(BMP-6) was added into the standard chondrogenic medium to improve TGF-β driven 
chondrogenesis of hASCs.209 To induce tenogenesis, hASCs at P3 were serum-starved overnight 
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at a density of 1×104 cells/cm2 in plate culture and at 6×104 cells/cm2 in scaffold culture, 
respectively. Cells were then treated with or without 10 ng/ml TGF-β3 (PeproTech) in basal 
medium (BM) consisting of high glucose DMEM, 1x Insulin-Transferrin-Selenium-X (ITS) and 
P/S (Gibco), and supplemented with 10% v/v of 1 mg/ml tECM, 1 mg/ml collagen type I 
solution (Col I, PureCol Advanced Biomatrix) or FBS for up to 14 days.  
3.2.8 Cell proliferation tests 
hASCs at P3 were plated on culture plastic and scaffolds at a density of 0.5×104 cells/cm2 and 
4×104 cells/cm2, respectively. Twenty-four hours after initial seeding, cells were fed with BM 
containing one of the following supplements at 10% v/v: 1 mg/ml tECM, 1 mg/ml Col I solution, 
or FBS. DMEM supplemented with 10% v/v Hanks’ Balanced Salt Solution (HBSS, Gibco) was 
used as a negative control. On days 0, 3 and 7, MTS assays (CellTiter 96 Assay, Promega) were 
performed to spectrophotometrically determine metabolic activity of cells from each group. 
Additionally, cells were nuclear stained by 4, 6-diamidino-2-phenylindole, dilactate (DAPI, Life 
Technologies) at each time point and imaged using an Olympus CKX41 inverted fluorescent 
microscope equipped with a CCD camera to reflect cell nuclei density.  
3.2.9 Real-time PCR analysis of gene expression  
Total cellular RNA was isolated on days 3, 7 and 14, after differentiation treatment (RNeasy, 
Qiagen) and first-strand cDNA was synthesized using the SuperScript III First-Strand cDNA 
synthesis kit (Invitrogen). Real-time PCR was performed using SYBR green Supermix in a Step 
One Plus real-time PCR system (Applied Biosystem, Life Technologies). The targets and 
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sequences of primers are shown in Supplemental Table 3. Relative expression level of each 
gene was normalized to that of 18S rRNA and calculated using the ∆∆Ct method.  
3.2.10 Protein extraction and Western blot assay 
Eight days after differentiation induction, total protein was extracted from each group by TM 
buffer (Total Protein Extraction Kit, Millipore) and concentrations were measured by BCA 
assay. Equal masses of reduced protein samples of the same concentration (~800 µg/ml) were 
electrophoretically separated in NuPAGE Bis-Tris Mini Gel (Life Technologies), and transferred 
onto PVDF membranes (iBlot dry blotting system, Invitrogen) for incubation with rabbit anti-
scleraxis (SCX) or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primary antibody 
(Abcam) at 4˚C overnight. Western blots were developed using horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG secondary antibodies (GE Healthcare Bio-Sciences) and West 
Dura Extended Duration Substrate (Thermo Scientific). 
3.2.11 Mechanical testing 
Tensile properties of scaffolds were analyzed using the Bose 3230 mechanical tester. Scaffolds 
were securely mounted between two clamps at 10 mm and loaded with uniaxial force applied at a 
displacement rate of 0.2 mm/s until 10 mm displacement. The tensile force and the displacement 
were recorded, and the slope of the linear portion of the stress–strain curve was calculated as 
Young’s modulus.  
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3.2.12 Matrix deposition and characterization 
hASCs were seeded on PCL scaffolds at a density of 6×104 cells/cm2 and cultured with BM 
supplemented with either 2% FBS or 2% FBS plus 10% tECM (v/v), in the presence of 50 
µg/mL ascorbate-2-phosphate (Sigma-Aldrich), for 3 weeks. Negative controls consisted of cell-
free scaffolds treated under the same conditions. Collagen content in each group was quantified 
using the Chloramine T-based hydroxyproline assay. Briefly, cell-seeded scaffolds were papain 
digested at 60 °C overnight, reacted with 4N NaOH, and then neutralized with HCl. The samples 
were then reacted with Chloramine T reagent (Fisher Scientific) and subsequently Ehrlich’s 
reagent (Sigma-Aldrich). Absorbance at 550 nm was measured spectrophotometrically by a 
microplate reader (BioTek). 
3.2.13 Immunofluorescent staining  
Cell-seeded scaffolds were washed in PBS, fixed in 4% paraformaldehyde, and blocked with 1% 
bovine serum albumin (BSA) and 22.52 mg/ml glycine in PBS-T. Primary antibodies used 
included goat anti-tenomodulin (Tnmd, 1:50, sc49325 Santa Cruz), or rabbit anti-Col I (1:500, 
ab34710 Abcam), with overnight incubation at 4 °C. Alexa Fluor 488 chicken anti-goat or Alexa 
Fluor 488 goat anti-rabbit were used as secondary antibodies at 1:500 dilution (Life 
Technologies). For F-actin staining, fixed cells were permeabilized in 0.1% Triton X-100 and 
then incubated with Alexa Fluor 488 phalloidin for 30 min at room temperature (Life 
Technologies). After nuclear counterstaining with DAPI (Life Technologies), cells were imaged 
using a confocal microscope (Olympus FluoView 1000).  
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3.2.14 Statistical analysis 
Data are presented as mean ± standard deviation (SD). All quantitative assays were performed 
for no less than three times independently (N equals to the number of independent tests in figure 
legends). In each replicate, cells from two donors were treated and analyzed separately in 
duplicate, and data were combined. One-way ANOVA with Bonferroni post hoc test and 
Student’s t-test were performed with SPSS (SPSS Statistics software 21, IBM) to determine 
statistical significance. Significance was considered at p<0.05. 
3.3 RESULTS 
3.3.1 Characterization of human ASCs 
After 14 days of culture, 28.83 ± 3.31% of the adherent cells isolated from the stromal vascular 
fraction (SVF) of adipose tissue were found proliferating by CFU assay, indicating a self-
renewal capability within the cell population. Upon induction of differentiation, the cultured cells 
at P2 were able to undergo differentiation toward multiple mesenchymal lineages, including 
adipogenesis, osteogenesis, and chondrogenesis (Figure 14A). Moreover, the phenotypic 
analysis by flow cytometry suggested a relatively homogeneous population that expressed 
mesenchymal cell markers (CD44, CD73, CD90 and CD105) while free of hematopoietic and 
endothelial markers (CD31, CD34, CD45) (Figure 14B).210 Taken together, these results 
confirmed that the cell population used for subsequent experiments exhibited characteristics 
consistent with ASCs derived from subcutaneous lipoaspirate. 
 71 
 
Figure 14. Characterization of hASCs. (A) Histological detection of ASC multipotency: 
Adipogenesis by Oil Red staining (red), osteogenesis by Alizarin Red staining (red), and 
chondrogenesis by Safranin-O staining (red). (B) Flow cytometry analysis of the cell surface 
markers characteristic for mesenchymal stem cells, hematopoietic and endothelial cells. 
3.3.2 Effect of tendon ECM on ASC behavior in 2D 
In order to investigate the role of tendon ECM in regulating ASC behavior, we extracted the 
soluble fraction of decellularized tendon ECM (tECM) from juvenile bovine SDF tendons. As 
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previously reported, the tECM solution prepared by this method is cell-free and rich in non-
collagenous ECM proteins, with a constant yield rate and consistent composition (Supplemental 
Figure 5).115 tECM or Col I solution were used at 1 mg/ml as medium supplements at 10% v/v 
to treat ASCs on 2D tissue culture plastic for up to 7 days. ASCs cultured with HBSS-
supplemented medium or FBS-supplemented medium (10% v/v) were used as negative and 
positive controls, respectively (Figure 15A). At days 0, 3, and 7, cell density and metabolic 
activity were determined by DAPI staining and MTS assay. After 7 days of culture, higher cell 
density in tECM and FBS-treated groups was clearly visualized by DAPI staining (Figure 15B). 
ASCs cultured with tECM for 7 days demonstrated significantly higher metabolic activity than 
those with Col I, the most abundant structural ECM protein in tendon tissue, but slightly lower 
than those cultured with FBS (Figure 15C).  
 
Figure 15. Assay of hASC proliferation in 2D cultures. (A) hASCs were plated on 2D tissue 
culture plastic, and treated with basal medium (BM) containing one of the following supplements 
at 10% v/v: HBSS, 1 mg/ml tECM solution (tECM), 1 mg/ml collagen type I solution (Col I) or 
FBS. (B) After 7 days of culture, DAPI nuclear staining showed high cell density in tECM- and 
FBS-treated groups. (C) MTS assay revealed elevated cellular metabolic activity in tECM- and 
FBS-treated groups. *, p<0.05; **, p<0.01; N=3. 
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The individual and combined effect of tECM and TGF-β3 on hASC tenogenesis was 
analyzed at the mRNA and protein level. Three types of medium (BM supplemented with 10% 
v/v FBS, Col I, or tECM) were prepared, with or without 10 ng/ml TGF-β3, in which ASCs were 
cultured for up to 14 days (Figure 16A). Real-time PCR analysis showed that treatment with 
tECM alone did not significantly increase the expression of SCX, the primary marker for early 
tendon differentiation. However, tECM combined with TGF-β3 gave rise to significantly higher 
levels of SCX expression than all other groups tested at days 3 and 7 (Figure 16B). The 
difference in SCX expression among the groups was confirmed at the protein level by Western 
blot (Figure 16D). Interestingly, unlike SCX, TNC expression was up-regulated by tECM 
treatment in the absence of TGF-β3 after 7 and 14 days of culture, while the combined treatment 
of tECM and TGF-β3 led to the highest level of TNC mRNA among all groups (Figure 16C). 
ASCs treated with TGF-β3 in the presence of Col I again showed delayed upregulation of tendon 
markers compared to the tECM plus TGF-β3 treatment (Figure 16C). Taken together, these data 
suggested that tECM treatment in 2D resulted in partial adoption of the tendon cell phenotype in 
the absence of other inductive cues, and enhanced tenogenesis of ASCs induced by TGF-β3. 
Moreover, tECM exhibited no such inductive effect on chondrogenesis of ASCs in 2D culture, 
suggesting a tissue-specific functionality of the tECM (Supplemental Figure 6).  
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Figure 16. Tenogenesis of hASCs in 2D cultures. (A) hASCs were plated on 2D tissue culture 
plastic, and treated with or without 10 ng/ml TGF-β3 in basal medium (BM) containing one of 
the following types of supplements at 10% v/v: FBS, 1 mg/ml tECM solution (tECM) and 1 
mg/ml collagen type I solution (Col I). (B, C) Real-time PCR analysis of (B) scleraxis (SCX) and 
(C) tenascin-C (TNC) expression levels. tECM treatment up-regulated SCX expression in the
presence of TGF-β3, and increased TNC expression with or without TGF-β3. (D) Western blot 
assay showed consistent difference in SCX protein. *, p<0.05; **, p<0.01; N=3. 
3.3.3 Characterization of the aligned microfiber scaffolds 
We next attempted to generate a physical scaffold environment that mimics the structural 
features of tendon. A microfibrous PCL scaffold was fabricated by electrospinning (Figure 
17A). Aligned scaffolds exhibited highly uniaxial fiber orientation: most fibers were oriented at 
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between 80° and 100° with respect to cross axis (Figure 17D,F), in contrast to the random 
orientation seen in the non-aligned scaffolds (Supplemental Figure 7). The mean thickness of 
aligned scaffold was 103.3 ± 18.9 µm (n=30). No significant difference in fiber diameter was 
found between aligned and random scaffolds (Figure 17E, 1.26 ± 0.51 µm vs. 1.29 ± 0.34 µm). 
When tension was applied in the direction of fibers, the aligned scaffolds displayed 2.5-fold 
higher tensile strength as compared to the randomly oriented scaffolds (Figure 17B,C). 
Anisotropy of the aligned scaffolds was confirmed by tensile testing along two planes: the elastic 
modulus along the axis of fibers (longitudinal) was 10-fold higher than that in the perpendicular 
direction (cross), as expected from the uniform orientation of fibers (Figure 17B,C). hASCs 
seeded on aligned scaffolds adopted elongated morphology and were orientated in the direction 
of fibers after 3 days of culture. In contrast, hASCs seeded on random scaffolds exhibited a 
polygonal shape without uniformity in orientation (Supplemental Figure 7). 
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Figure 17. Characterization of electrospun PCL scaffolds. (A) Gross appearance of scaffold. 
(B) Strain-stress curves indicated dramatic difference in tensile strength between aligned and 
random scaffolds; anisotropy in tensile strength was found in aligned scaffolds (Aligned longi vs. 
Aligned cross). (C) In aligned scaffolds, the elastic modulus was the highest in the longitudinal 
direction (Aligned longi vs. Aligned cross), which was also significantly higher than that of 
randomly-oriented scaffolds (Random longi, Random cross). *, p<0.05; N=3. (D) SEM image of 
aligned microfibrous PCL scaffolds. (E) Distribution of fiber diameters. (F) Most fibers in the 
aligned scaffold were oriented at between 80° and 100° with respect to cross axis. 
3.3.4 Effect of tendon ECM on ASC behavior in scaffolds 
ASCs seeded on aligned scaffolds were treated for one week in BM supplemented with 10% v/v 
FBS, Col I, or tECM. No observable differences in cell shape were found among groups; most 
ASCs cultured on the aligned scaffolds were elongated and aligned in the direction of the 
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surrounding fibers regardless of treatment method, as indicated by immunofluorescent staining 
of F-actin (Figure 18A). Nevertheless, cell metabolic activity differed greatly among groups: the 
tECM-treated group exhibited enhanced metabolic activity compared to Col I- or HBSS-treated 
groups. At day 7, the metabolic activity of tECM-treated cells remained significantly higher than 
Col I- or HBSS-treated cells, and was comparable to FBS-treated cells (Figure 18B).  
 
Figure 18. Behavior of hASCs seeded on aligned scaffolds. Cultures were treated with basal 
medium (BM) containing 10% v/v FBS, Col I, or tECM. (A) After 3 days of culture, most ASCs 
cultured on aligned scaffolds were elongated and aligned regardless of treatment condition. 
Green: F-actin; blue: DAPI. (B) MTS assay showed enhanced cellular activity in the tECM-
treated group compared to Col I- or HBSS-treated groups, which was comparable to FBS-treated 
cells at day 7. *, p<0.05; N=3. 
 
Given the established positive influence of fiber alignment on tenogenic differentiation, 
analysis of gene expression and matrix deposition were only performed on aligned microfibrous 
scaffolds. When cultured in BM with TGF-β3 and 2% FBS, SCX expression in hASCs was 
increased by the presence of tECM on days 3, 7 and 14, whereas in the Col I group the up-
regulation in SCX was not seen until day 14 (Figure 19A). Similarly, tECM supplementation 
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resulted in significantly higher TNC levels compared to controls at all three time points tested. In 
contrast, Col I treatment did not significantly up-regulate TNC levels although there was a trend 
of increase (Figure 19A). To further investigate the extent of tECM-mediated tenogenesis, we 
analyzed the presence of Tnmd, a tendon-specific membrane glycoprotein found in the late phase 
of differentiation, by immunofluorescent staining. Compared to other treatment groups, an 
evidently higher density and intensity of staining for Tnmd (green) was seen in the tECM-treated 
group (Figure 19B).  
 
Figure 19. Tenogenic differentiation of hASCs seeded on aligned scaffolds. (A) Real-time 
PCR assay showed that scleraxis (SCX) and tenascin C (TNC) expression was significantly 
increased in the presence of tECM. (B) Immunofluorescence showed that staining for 
tenomodulin (Tnmd) was denser and more intense (green) in tECM-treated group. *, p<0.05; **, 
p<0.01; N=4. 
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We next examined the influence of tECM on the synthesis and organization of collagen, 
the primary structural protein of tendon tissue. Cells seeded on PCL scaffolds were treated with 
L-ascorbate 2-phosphate for 3 weeks to accelerate collagen synthesis. Immunofluorescent 
staining of Col I on the surface of scaffolds qualitatively confirmed the presence of newly-
synthesized matrix in both the control and tECM-treated groups, revealing arrays of collagen 
fibrils extended in the direction of the PCL fibers. Interestingly, denser collagen fibrils were 
found on scaffolds treated with tECM (Figure 20A) compared to those treated with FBS only, 
while the amount of collagen presented by tECM alone on the acellular scaffolds was negligible. 
(Figure 20A). This was expected, as tECM is composed of a high ratio of non-collagenous 
proteins (Supplemental Figure 5). The observed difference in collagen content was confirmed 
quantitatively by hydroxyproline assay. In the presence of tECM, hASCs produced a 2.4-fold 
higher amount of collagen per scaffold than controls (86.54 ± 7.46 vs. 36.79 ± 2.49 µg/scaffold). 
This pattern persisted when collagen content was normalized against double stranded DNA 
(dsDNA) content, with a 1.8-fold higher collagen content per unit weight of dsDNA (145.05 ± 
17.46 vs. 80.02 ± 17.77 µg/µg DNA) in the tECM-treated group vs. control group.  
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Figure 20. Matrix deposition by hASCs cultured on aligned scaffolds. (A) 
Immunofluorescent staining for collagen type I (green) found denser collagen fibrils deposited 
by cells treated with tECM compared to the control group. (B) Hydroxyproline assay showed 
higher collagen content in the tECM-treated group. Collagen content of each group was 
normalized to that of the corresponding cell-free group. **, p<0.01; N=3. 
3.4 DISCUSSION 
The goal of this study was to investigate the modulatory effect of soluble tendon ECM (tECM) 
on known biochemical (i.e. TGF-β3) and biophysical cues that promote tendon differentiation, in 
order to advance the development of functional engineered tendon grafts. Human ASCs were 
prepared and characterized, and individual and combined effects of tECM and TGF-β3 on cell 
behavior, including proliferation and differentiation, were examined. We found that: (1) tECM 
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enhanced TGF-β3-induced tenogenesis of hASCs in both 2D plastic and 3D scaffold cultures, 
and (2) tECM favorably modulated matrix deposition and organization by hASCs seeded on 
microfibrous scaffolds. 
In the native tendon microenvironment, dense ECM surrounds the tendon cell. Tendon 
stem/progenitor cells (TSPCs) exhibited impaired proliferative and tenogenic potential in the 
absence of critical ECM proteins,201 and showed reduced TNMD expression when seeded on 
tissue culture plastic, as compared to tendon ECM.211 The tECM prepared in our study increased 
hASC proliferation and TNC expression when used as a culture supplement in the absence of 
other inductive cues. Expression of both TNC and SCX was further enhanced when treated 
concomitantly with TGF-β3, as shown in both 2D plastic and 3D scaffold cultures. Our findings 
indicate that the regulatory effects of tECM on tendon cell behavior also apply to ASCs. 
Consistent with our results, Little et al.102 found increased proliferation and partial adoption of 
tendon phenotype by ASCs seeded on acellular tendon/ligament matrix. The tECM contains not 
only collagen but also a number of non-collagenous proteins, including fibronectin, 
fibromodulin, biglycan and decorin, all of which are known to regulate MSC activities, such as 
adhesion, proliferation, stemness, and differentiation.212-215 In addition, a variety of growth 
factors, such as TGF-β, IGF-1, VEGF, and CTGF, were found embedded in the decellularized 
tECM.216 How these bioactive molecules, along with other yet-to-be-identified components in 
the tECM, contribute to the bioactivity of the tECM in our results remains to be investigated. The 
enhancement of ASC tenogenesis by tECM combined with TGF-β3 treatment exemplifies the 
complexity in the fine control of tissue differentiation – tECM may serve as a reservoir of signals 
by itself or, not mutually exclusively, exert a regulatory effect on exogenous inductive cues.214 
Moreover, we found little inductive effect of tECM on chondrogenesis, in agreement with our 
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earlier work (Chapter 2). This finding further highlights the tissue specificity of the derivation of 
ECM in influencing MSC differentiation. 
To date, ASCs are widely used for scaffold recellularization and as a means to improve 
vascularization, matrix deposition, and implant integration,217-220 whereas optimization of 
tendon-specific differentiation of seeded ASCs remains elusive. On one hand, ASCs isolated 
from a variety of animal species have been reported to upregulate tenogenic markers in vitro 
under specific treatments,184,185,189,191,221 suggesting the tenogenic potential of ASCs. On the other 
hand, Eagan et al. questioned the suitability of hASCs for tendon tissue engineering and reported 
the lack of any significant and consistent upregulation in the expression of COL I, TNC, or SCX, 
in hASCs treated for up to 4 weeks with TGF-β1 or IGF1.222 In addition, hASCs showed lower 
SCX expression compared to TSPCs when cultured in vitro.223 Incorporating tissue-specific 
ECM molecules into differentiation protocols represents an alternative approach to develop a 
robust tenogenesis strategy for ASCs in order to better exploit the regenerative potential of ASCs 
applied to tendon tissue engineering. In future studies, more tendon phenotypic markers, such as 
Mohawk (MKX), and ECM protein encoding genes should be analyzed to advance our 
knowledge of the pro-tenogenic effect of tECM.224      
As noted above, the scaffold is another key component in tendon tissue engineering by 
creating a proper microenvironment for mechanical support and tissue regeneration. Therefore 
we prepared electrospun, aligned fibrous PCL scaffolds consisting of microfibers (~1.3 µm) to 
simulate the size of collagen fibrils in natural tendon tissue.225 The diameter of fibers has been 
found to have an influence on seeded cells; compared with nanofibers, microfibers promoted the 
expression of phenotypic markers of tendon fibroblasts, possibly due to the resemblance of the 
healthy, mature matrix with micron-sized collagen fibrils.226,227 A promising future prospect 
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based on this work is the application of dynamic/cyclic stretch to cell-seeded scaffolds to 
simulate the loading of native tendon during motion.228 Moreover, the PCL scaffold used here 
may be further modified to address some of the current limitations. For instance, although the 
aligned scaffold demonstrated anisotropy similar to that of tendon tissue, improvements in 
tensile strength is clearly needed if intended to be used as a clinical tendon graft.229 In addition, a 
functional implant will likely require a scaffold that sufficiently retains bioactive agents. For this 
purpose, scaffold surface modification may be carried out to immobilize bioactive 
macromolecules contained in tECM.230 Likewise, scaffold thickness and porosity may need to be 
improved to allow sufficient cell infiltration.231 
We examined the influence of tECM on collagen synthesis and organization by hASCs 
seeded on aligned scaffolds. Consistent with previous studies, collagen fibrils were aligned in the 
direction of the PCL fibers.231 More abundant and homogenous distribution of collagen fibrils 
were found in cells treated with tECM. The tECM-induced enhancement of collagen 
fibrillogenesis may be due to the bioactivity of small leucine-rich proteoglycans (SLRPs) and 
glycoproteins in tECM, such as decorin, biglycan, lumican, and collagen oligomeric matrix 
protein (COMP). These proteins are able to bind non-covalently to collagen molecules at specific 
sites in the gap region of fibrils and therefore facilitate collagen fibrillogenesis and 
stabilization.232-235 Acellular scaffolds possessed negligible collagen content when treated with 
tECM.  This confirms that the tECM acts by promoting collagen production in ASCs rather than 
by merely adsorbing to the scaffold. 
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3.5 CONCLUSIONS 
In this study, a bioactive, soluble fraction of tendon ECM (tECM) was prepared, characterized 
and incorporated into growth/differentiation medium to treat ASCs. We demonstrated that tECM 
treatment enhanced the proliferation and tenogenic capacity of hASCs. Moreover, when cultured 
on scaffolds that mimic the architecture of native tendon tissue, hASCs treated with tECM 
exhibited increased Col I matrix synthesis and improved organization. These findings provide 
new insights into the role of tissue-specific ECM in guiding site-appropriate cell responses in 
terms of connective tissue differentiation and healing. In addition to serving as an in vitro 
differentiation model, the design attributes of the scaffold culture system developed in this study 
are applicable to functional tendon tissue engineering that aims at simultaneous induction of 
phenotypic markers and enhanced matrix deposition. Our findings highlight the importance of 
reproducing the native tissue microenvironment as a design principle for eliciting desired cellular 
responses for tissue regeneration.  
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4.0  MENISCUS TISSUE ENGINEERING – COMBINING REGION-SPECIFIC 
BIOACTIVITY OF SOLUBLE INNER AND OUTER MENISCAL-DERIVED 
EXTRACELLULAR MATRICES WITH PHOTOCURABLE HYDROGELS 
As shown in the preceding chapters, urea-extracted fractions of decellularized tendon and 
cartilage ECMs are able to promote tissue-specific cell phenotypes in various culture 
microenvironments.  In these experiments, the entire tissue was homogenized prior to 
decellularization and solubilization, without regard to any regional differences in ultrastructure 
or biochemical composition.  However, the meniscus contains profound regional differences 
when moving radially from the central to peripheral zones.  In particular, the central region more 
closely resembles hyaline cartilage while the peripheral region resembles tendon/ligament.  In 
this chapter, we explore the region-specific bioactivity of urea-extracted fractions derived from 
ECM of the inner and outer meniscal regions.  In Section 4.1, soluble meniscal ECM from either 
region was added to photocrosslinkable polyethylene glycol diacrylate (PEGDA) hydrogels 
seeded with human bone marrow MSCs.  PEG provides a 3D structure in which MSCs can 
deposit matrix, but it lacks bioactive motifs (e.g., cell-binding domains) found in natural ECM 
structural proteins (e.g., collagen).  As a result, PEGDA hydrogels serve as a relatively inert 3D 
microenvironment in which any differences between groups can be attributed to the urea-
extracted meniscus ECM. Section 4.2 expands on the results of Section 4.1 through additional 
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characterization of the soluble ECM fractions.  GelMA hydrogels are used in place of PEGDA, 
as we’ve previously shown the former to support roust chondrogenesis in seeded MSCs.134 As 
GelMA contains cell-binding domains found in native collagen, it may possess an inherent 
bioactivity that could influence the region-specific effects of soluble meniscus ECM.  
Collectively, the work presented in this chapter demonstrates the homologous bioactivity of 
urea-extracted fractions of soluble ECM derived from the inner and outer meniscal regions, 
which may serve to enhance hydrogels intended for meniscus tissue engineering. 
4.1 REGION-SPECIFIC BIOACTIVITY OF SOLUBLE INNER AND OUTER 
MENISCAL-DERIVED EXTRACELLULAR MATRICES IN PHOTOCURABLE 
POLYETHYLENE GLYCOL DIACRYLATE (PEGDA) HYDROGELS 
The following section contains material from the accepted publication: 
Shimomura K, Rothrauff BB, Tuan RS. 2016. Region-specific effect of decellularized 
meniscus extracellular matrix on mesenchymal stem cell-based meniscus tissue engineering.  
American Journal of Sports Medicine. [Accepted] 
4.1.1 Introduction 
The meniscus plays important roles in the knee joint, including force transmission, shock 
absorption, joint lubrication, and provision of joint stability.236-240 Unfortunately, many athletes 
suffer injury to the knee meniscus, and the effective repair of such injuries remains a challenge in 
such a young and active population.241-243 Importantly, it is widely accepted that a meniscal tear 
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does not heal spontaneously owing to limited blood supply.244-246 Without effective long-term 
repair for these injuries, the damage to the knee may compromise athletic careers and lead to 
osteoarthritis (OA) at an early age.247,248 Therefore, the development of novel therapeutic 
methods for meniscal repair is both timely and necessary. 
Recently, tissue engineering approaches that involve the use of adult tissue-derived 
multipotent mesenchymal stem cells (MSCs) and biomaterial scaffolds have gained increasing 
attention as potential regenerative therapies, including musculoskeletal regeneration. While a 
number of meniscal biomaterial scaffolds have been developed and shown promise, complete 
meniscal regeneration remains challenging because of the difficulty in reproducing the 
anatomically complex meniscal structure composed of region-specific matrix organization and 
biochemical composition.249-251 Recently, decellularized, tissue-derived extracellular matrices 
(ECMs) have been tested as candidate scaffolds because they are considered potentially 
beneficial to tissue development via regulation of cell proliferation and differentiation by 
providing specific molecules that guide cell behavior and morphogenesis.6,252 It is also generally 
assumed that tissue-derived ECMs retain bioactivities specific to their tissue origin.115 A 3D 
collagen-based scaffold combined with water-soluble decellularized ECMs derived from native 
tendon tissue has been recently developed, and proved its feasibility in developing an MSC-
seeded, tendon ECM-containing construct for tendon tissue engineering.115 Considering the 
structural similarities between tendons and menisci, including dense ECM components as well as 
their hypocellular and hypovascular nature, meniscus-derived ECM (mECM) may offer similar 
benefit for meniscus tissue engineering. 
  It is noteworthy that menisci have different characteristics across the inner and outer 
regions. In particular, there are regional differences in collagen ultrastructure and biochemical 
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composition, with resident meniscal cells having distinct morphologies and biological properties 
dependent on their location.253,254 Histological and immunohistochemical analyses by Chevrier et 
al.255 on human, sheep, and rabbit menisci showed that collagen type I appeared throughout most 
of the meniscus, while collagen type II was present primarily in the inner main meniscal body. 
The inner region of menisci was also the glycosaminoglycan (GAG)-rich area. These studies 
therefore indicate that the inner region of menisci should be considered to have a 
fibrocartilaginous phenotype, while the outer region of menisci exhibits a fibroblastic phenotype. 
In applying mECM for meniscus tissue engineering, it is important to consider these differences 
in structural and biochemical features between the inner and outer regions.  
  This study investigates the feasibility of applying water-soluble mECM combined with 
a polyethylene glycol diacrylate (PEGDA) hydrogel-based scaffold for meniscal tissue 
engineering, specifically comparing the effects of region-specific mECMs on 3D constructs 
using multipotent, human bone marrow-derived MSCs (hBMSCs).  PEDGA provides a 
cytocompatibility 3-dimensional microenvironment without additional cell-binding motifs found 
on other hydrogel polymers (e.g., collagen, fibrin).  As a result, differences in hBMSC behavior 
can be attributed to compositional differences between region-specific mECM extracts.  It is 
hypothesized that mECM derived from the inner or outer region will direct the differentiation of 
hBMSCs in a regionally specific manner.  In turn, this region-specific bioactivity may be utilized 
for future applications in meniscal tissue engineering. 
4.1.2 Methods 
4.1.2.1 Extraction and preparation of mECM  Meniscal tissue specimens were harvested 
from the hind-leg stifle of 2- to 3-year-old cows within 24 hours of slaughter (JW Trueth and 
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Sons, Baltimore, MD).  Bovine menisci have been shown to have homologous structure and 
function to human menisci52,256 and the relatively large size257 provides a inexpensive source of 
meniscal ECM. Preparation of mECM was carried out using the recently published protocol for 
tendon ECM.115 The menisci were divided precisely along the midline separating the inner and 
outer halves.  The tissues were then minced separately into small pieces (~8 mm3), decellularized 
by incubation in 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in phosphate-buffered saline 
(PBS; pH 7.4) under continuous agitation at 4 °C for 3 days, followed by three washes, 30 min 
each, in PBS. The decellularized material was then treated with 200 U/ml DNase and 50 U/ml 
RNase (Worthington, Lakewood, NJ) solution at 37°C for 24 h and then washed in PBS (6 times, 
30 min for each wash). After nuclease digestion, decellularization was verified by the lack of cell 
nuclei using DAPI staining and by the reduction in double-stranded DNA content using 
PicoGreen® dsDNA Quantitation Reagent and Kits (Invitrogen, Carlsbad, CA), compared to that 
of native meniscal tissues. After the confirmation of successful decellularization, each tissue was 
cryomill-powderized using Freezer/Mill® (SPEX Sample Prep, Metuchen, NJ), and then 
extracted with 3 M urea (Sigma-Aldrich, St. Louis, MO) in water (25 mg mECM powder/ml) 
with gentle agitation at 4°C for 3 days. The suspension was then subjected to centrifugation for 
30 min at 1,500 x g to collect the extract supernatant. Urea was removed by dialysis in 2000 
MWCO dialysis tubing (Sigma-Aldrich, St. Louis, MO) against deionized water at 4°C for 2 
days. Water was changed every 4 h. The dialyzed mECM extract was transferred into centrifugal 
filter tubes (3000 MWCO, Millipore, Carrigtwohill, Ireland) and spin-concentrated for 30 min at 
1,500 x g. The final mECM solution was filter-sterilized through PVDF syringe filter units (0.22 
µm, Millipore, Billerica, MA), and the total protein concentration determined using the BCA 
assay (Thermo Fisher Scientific, Waltham, MA). The mECM preparations were stored as 
aliquots of 600 µg/ml at -20 °C until use.  
4.1.2.2 PEGDA preparation  5 g polyethylene glycol (PEG, 4 kd, Fluka, Milwaukee, 
WI) was dissolved in 15 ml anhydrous dicholoromethane (DCM) followed by the addition of 
0.44 ml methacrylic anhydride (MA), 0.25 ml triethylamine (TEA), and 3 g molecular sieves. 
The solution was thoroughly mixed and protected from light, and allowed to react at room 
temperature for 4 days. The final PEGDA suspension was filtered to remove the solvent and 
dried overnight under high vacuum. The dried PEGDA was then dissolved in H2O at 30% 
concentration (w/v) and dialyzed in 2000 MWCO dialysis tubing (Sigma-Aldrich) against H2O 
to completely remove all low-molecular-weight contaminants. 
4.1.2.3 Cell isolation   hBMSCs were isolated from bone marrow aspirate from the 
femoral head of three patients undergoing total hip arthroplasty with Institutional Review Board 
approval (University of Pittsburgh) and cultured in growth medium (DMEM-high glucose, 10% 
fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin, Invitrogen, Carlsbad, 
CA) and passaged. All experiments were performed with hBMSCs at passages 3-5. 
4.1.2.4 Fabrication of 3D construct  hBMSCs were trypsinized from cell culture flasks 
and mixed at 1 x 106 cells/ml with 10% PEGDA, containing a final concentration of either 60 
μg/ml (see below) inner mECM or outer mECM. A control group was prepared without mECM 
supplementation. These solutions (500 μl per construct in 24 well culture plates) were mixed 
with 0.125% lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) as used in a previous 
study,258 and then photocrosslinked to fabricate hydrogel scaffold-based 3D constructs. The cell-
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seeded constructs were cultured with chondrogenic medium containing Dulbecco’s Modified 
Eagle’s Medium (DMEM)-high glucose (Invitrogen), containing 100 units/ml penicillin and 100 
μg/ml streptomycin, ITS Premix (BD Biosciences, Franklin Lakes, NJ), 50 μg/ml ascorbic acid 
2-phosphate (Sigma-Aldrich), 40 μg/ml L-proline (Sigma-Aldrich), 100 μg/ml sodium pyruvate
(Life Technologies, Carlsbad, CA), 0.1 μM dexamethasone (Sigma-Aldrich), and 10 ng/ml 
recombinant human transforming growth factor-β3 (TGF-β3; PeproTech, Rocky Hill, NJ).  
4.1.2.5 Cell viability assay  On culture days 1 and 7, the 3D constructs (n = 2 per group) were 
washed twice with PBS and cell viability was assessed with the Live/Dead stain (Invitrogen, San 
Diego, CA), and examined by epifluorescence microscopy (live cells stained green, dead cells 
stained red). Using four different microscopic views of the samples from each group, live and 
dead cells were counted to calculate cell viability, represented as the percentage of number of 
live cells as a function of total number of cells (live plus dead). 
4.1.2.6 Real-time PCR analysis  On culture days 1, 3, and 7, total RNA was isolated from 
the 3D constructs (n = 4 or 5 per group, per culture day) using an RNA extraction Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s protocol. First-strand cDNA was synthesized 
with random primers using a cDNA synthesis kit (Invitrogen, Carlsbad, CA). Quantitative real-
time PCR (qRT-PCR) was performed using SYBR green Supermix in a Step One Plus real-time 
PCR system (Applied Biosystem, Life Technology) and then analyzed by comparative Ct 
quantification (delta delta Ct method). Primers used for meniscus-associated gene expression 
included those for collagen type I, collagen type II, aggrecan, and Sox 9. The targets and 
sequences of primers are shown in Table 1. The expression level of each gene was normalized to 
GAPDH. 
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Table 1. Primer sequences for real-time PCR 
4.1.2.7 Quantification of collagen based on hydroxyproline assay  On culture day 28, the 
collagen content of 3D constructs (n = 4 per group) was estimated by hydroxyproline 
quantification. The constructs were digested with papain (Sigma-Aldrich) at 60°C overnight. 
After treatment with 4N sodium hydroxide, the samples were heated to 120 °C for 20 min, and 
then neutralized with 4N hydrochloric acid. The samples were then oxidized with chloramine-T 
at room temperature for 20 min, and reacted with Ehrlich’s reagent at 65°C for 20 min, following 
which A550 of each sample was measured spectrophotometrically. Hydroxyproline contents were 
calculated based on a calibrated standard curve.   
4.1.2.8 Quantification of glycosaminoglycan (GAG)   On culture day 28, the sulfated GAG 
(sGAG) content of 3D constructs (n = 4 per group) was determined. Papain-digested samples 
(see above) were reacted using a Blyscan Glycosaminoglycan Assay Kit (Biocolor Ltd, 
Carrickfergus, United Kingdom) according to the manufacturer’s protocol. Dilutions of provided 
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chondroitin 4-sulfate were used to generate a standard curve.  The Blyscan dye reagent, 
containing 1,9-dimethylmethylene blue (DMMB), binds proportionately to the sGAG in the 
sample. Absorbance of each sample was measured at 656 nm with a spectrophotometer, and the 
sGAG contents of 3D constructs were calculated from the standard curve. 
4.1.2.9 Statistical analysis  Statistical analysis was performed using analysis of variance 
(ANOVA) followed by post-hoc testing for DNA contents, qPCR, and quantification of 
hydroxyproline and GAG synthesis. The results are presented as mean ± SD. The data were 
analyzed with SPSS 21.0 (IBM SPSS, Chicago, IL) and significance was set at p < 0.05. 
4.1.3 Results 
4.1.3.1 Decellularization of mECM  Decellularization after Triton X-100 and subsequent 
nuclease treatment was verified by the absence of cell nuclei using DAPI staining (Figure 21A-
D). Also, the DNA contents of meniscal tissues from both the inner or outer regions were 
significantly reduced by Triton X-100 and subsequent nuclease treatment, compared to that of 
original meniscal tissues (native versus decellularized inner meniscus: 168±87 ng/mg versus 
22±15 ng/mg, p=0.0056; native versus decellularized outer meniscus: 133±40 ng/mg versus 
12±7 ng/mg, p=0.0004 (Figure 21E). 
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Figure 21. Preparation of decellularized mECM. DAPI staining of meniscal tissues from inner 
region (A, C) and outer regions (B, D). Meniscal tissues in both groups (A, B) were successfully 
decellularized after sequential treatment with Triton X-100 and subsequent nuclease digestion 
(C, D). Scale bar = 100 μm. Also, DNA contents of meniscal tissues in both groups were 
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substantially reduced by combined Triton X-100 and nuclease treatment (E). *, p<0.05; **, 
p<0.01. 
4.1.3.2 Extraction of mECM  After the decellularization process, the extraction of water-
soluble mECM with urea was verified by the BCA assay, in which the amount of total protein 
was stably obtained at > 600 μg/ml. Based on these results, we set the concentration of mECM at 
60 ug/ml for the production of 3D constructs based upon the 10% v/v supplementation ratio used 
in our previous study on soluble tendon ECM.115 
4.1.3.3 Cell viability  Live/Dead assay demonstrated that high percentages of viable 
cells were seen on day 1 in each group (control, 90.5%±4.5%; inner, 87.1%±6.9%; and outer, 
79.4%±2.0%) (Figure 22A,C), indicating that the mECM solution was non-toxic to cells. 
After 7 days of culture, cells continued to retain a high rate of viability in each group 
(control, 93.5%±1.0%; inner, 91.7%±4.5%; and outer, 88.2%±8.2%) (Figure 22B, C).  
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Figure 22. Viability of hBMSCs seeded in mECM-enhanced hydrogels. Live/Dead cell 
viability staining (green, live cells; red, dead cells) showed a high percentage of viable cells in all 
culture groups (control, inner ECM, and outer ECM) on culture day 1 (A) and day 7 (B). Scale 
bar = 100 μm. (C) Quantification of cell viability. A high percentage of viable cells was seen in 
all groups.  
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4.1.3.4 Expression profiles of meniscus-associated genes   qPCR showed that 
supplementation with mECM increased the relative level of collagen type I mRNA on culture 
day 7, with the outer mECM group producing a higher level of collagen type I than the inner 
mECM group (9.8±6.0 versus 5.2±1.2, p=0.0378) and the control group (9.8±6.0 versus 
1.0±0.78, p=0.0033) (Figure 23A). On the other hand, the level of collagen type II mRNA in the 
inner mECM group was significantly higher than that in the outer mECM group (3.1±1.1 versus 
1.4±0.52, p=0.0092) and control group (3.1±1.1 versus 1.0±0.18, p=0.0019) at day 7 (Figure 
23B). Similar to the expression of collagen II, the level of aggrecan mRNA in the inner mECM 
group was significantly higher than that in the outer mECM group (2.6±0.52 versus 1.8±0.33, 
p=0.0308) and control group (2.6±0.52 versus 1.0±0.16, p=0.0006) at day 3, and remained 
higher than the control group (3.0±1.5 versus 1.0±0.24, p=0.0159) by day 7 (Figure 23C). 
Finally, the mRNA level of Sox9 was significantly increased in both inner (2.3±0.59 versus 
1.0±0.35, p=0.0070) and outer mECM group (2.6±0.15 versus 1.0±0.35, p=0.0028) at day 3, 
compared with control group, and then decreased to a similar level to the control group at day 7 
(Figure 23D). 
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Figure 23. The effect of mECM on gene expression. Expression of meniscus-associated genes 
in chondrogenic cultures of hBMSC-seeded hydrogel constructs analyzed by real time qPCR at 
days 1, 3, and 7. (A) Collagen type I, (B) collagen type II, (C) aggrecan, and (D) Sox9. Note that 
collagen type I expression was significantly higher in the outer mECM group, while the 
expression of collagen type II and aggrecan in the inner mECM group was significantly higher 
than in other groups. *, p<0.05; **, p<0.01. 
4.1.3.5 Quantification of hydroxyproline and GAG synthesis  Supplementation with mECM 
increased hydroxyproline content, which was higher in the outer mECM group compared with 
the inner mECM group (21.7±5.9 μg/culture versus 12.5±3.3 μg/culture, p=0.0408) and control 
group (21.7±5.9 μg/culture versus 7.0±3.7 μg/culture, p=0.0029) (Figure 24A) on day 28. At the 
same time, increases in GAG content were also observed upon treatment with mECM, with both 
inner (21.8±6.1 μg/culture versus 6.7±3.8 μg/culture, p=0.0131) and outer mECM groups 
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(20.4±7.0 μg/culture versus 6.7±3.8 μg/culture, p=0.0214) being significantly higher than that of 
the control group (Figure 24B). 
Figure 24. The effect of mECM on hydrogel biochemical composition. Collagen 
(hydroxyproline) and GAG contents in long-term chondrogenic cultures of hBMSC-seeded 
hydrogel constructs at day 28. (A) Hydroxyproline content in the outer mECM group was 
significantly higher than that of other groups. (B) GAG content in the inner and outer mECM 
groups were both significantly higher than that of the control group. *, p<0.05; **; p<0.01. 
4.1.4 Discussion 
The findings reported here demonstrated that 3D constructs produced using hBMSCs seeded in a 
photocrosslinked hydrogel scaffold and treated with the chondrogenic agent, TGF-β3, actively 
responded to treatment with mECM. Exposure to mECM did not compromise cell viability and 
resulted in long-term gain in collagen and GAG production. Interestingly, inner and outer 
regions of the meniscus appear to produce ECM with different compositions. Gene expression 
analysis of genes showed that supplementation with inner mECM increased the mRNA 
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expression level of collagen type II and aggrecan, associated with a cartilaginous phenotype, as 
well as Sox 9, a transcription factor associated with chondrogenic induction. On the other hand, 
the supplementation with outer mECM more strongly increased the mRNA expression level of 
collagen type I. In addition, collagen (hydroxyproline) content was highest in the outer mECM 
group, while sGAG content was equally elevated by both mECM groups, compared to control. 
Based on these findings, we concluded that inner mECM enhances fibrocartilaginous 
differentiation of hBMSCs, while outer mECM promotes a more fibroblastic phenotype. 
Although the importance of preserving the meniscus for optimal knee joint function is 
well recognized,246,259-261 meniscectomies remain the gold standard for meniscal tears given the 
poor intrinsic healing capacity of the meniscus.244,262 Therefore, a new therapeutic method for 
meniscal repair or regeneration with high clinical relevance is urgently necessary. Nevertheless, 
meniscal regeneration has remained highly challenging. It is technically difficult to artificially 
reproduce meniscal structure because of the highly complex biochemical and anatomical features 
of the meniscus.255 In particular, the meniscus is known to exhibit regional structural, 
biochemical, and cellular differences between its fibrocartilaginous inner and fibroblastic outer 
zones.253,255 In this study, we have successfully extracted water-soluble mECM, similar to recent 
work on tendon ECM,115 and demonstrated that the application of both inner and outer mECM to 
meniscal tissue engineering could contribute to the production of such biphasic meniscal 
structure, correspondent with previous morphological and biological studies.253-255. Taken 
together, these results suggest the feasibility of fabricating bioactive scaffolds using region-
specific meniscus ECM preparations for meniscus tissue engineering, which may have 
significant clinical relevance. 
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A number of meniscal implants have recently been developed, and some of them are 
already used in clinical practice.263-267 These implants are commonly monophasic implants that 
do not take into account the differences between the inner and outer regional structural and 
biological properties as mentioned above, although the consideration of these regional 
differences should be critical for complete meniscus regeneration. We believe that zonal 
regeneration of inner and outer regions is needed to improve repair quality, i.e., engineered 
implants should be fabricated such that the inner and outer regions are already pre-arranged and 
pre-formed in a structurally relevant manner.  
  Recent work of tendon-derived ECM (tECM) revealed that soluble tECM isolated from 
bovine tendons contains not only collagen but also numerous low molecular-weight, non-
collagenous proteins, including fibronectin, fibromodulin, biglycan and decorin, all of which are 
known to regulate MSC behavior.115 Considering the structural and compositional similarities 
between tendons and menisci, it is likely that the cocktail of low molecular-weight, non-
collagenous components derived from mECM may serve important signaling activities to 
promote meniscal morphogenesis in a regional specific manner. While identification of the 
numerous proteins comprising the mECM extracts was beyond the scope of the study, it is likely 
that unique combinations of growth factors found in each are responsible for directing the noted 
region-specific differentiation of hBMSCs. Equally plausible, components of the mECM extract 
may bind to cell adhesion receptors (e.g., integrins) and/or modify growth factor receptor activity 
(e.g., TGF-β receptor) to modulate the specific bioactivity of exogenous growth factors added as 
medium supplements.  Future studies will explore both the composition of mECM extracts and 
the mechanisms underlying their region-specific effects. 
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Decellularized ECM scaffolds have been previously applied as regenerative medicine 
strategies for tissue and organ replacement, and some of them, including ECM products derived 
from dermis, urinary bladder, small intestine, mesothelium, pericardium, and heart valves, are 
already used in clinical practice.6 Numerous decellularization techniques have been explored 
(e.g., chemical, enzymatic, and physical), the optimal combination of which depends on the 
tissue cellularity and structure.115,268-270 Successful decellularization has been defined as <50 ng 
dsDNA per mg ECM dry weight and lack of visible nuclear material in tissue sections stained 
with DAPI or H&E.6 Our decellularization technique, combining a detergent and nucleases, 
significantly reduced the DNA content and showed the absence of cellular nuclei by DAPI 
staining. Therefore, it should be considered as a suitable technique for meniscal 
decellularization. 
Our findings suggest that inner and outer mECM preparations may be applied, e.g., using 
PEG-based hydrogel, in a regionally defined manner, to engineer a meniscus-like tissue that 
mimics the anatomy and biochemistry of native meniscus. With recent advancements of scaffold 
fabrication techniques, including 3D printing,258,271 we are working to combine region-specific 
mECM with printable polymers to fabricate an anatomic meniscus substitute. To that end, 
hBMSCs could be homogenously distributed within a meniscus-shaped hydrogel with 
subsequent adoption of a region-appropriate cell phenotype guided by the surrounding mECM 
extract.  Ultimately, we hope to leverage this technology to develop novel grafts and/or in situ 
biologics capable of enhancing meniscus healing and preserving joint health. 
In order to achieve these future directions, several limitations of the present study must 
be addressed. First, we did not perform biomechanical testing on the constructs. Sufficient 
mechanical integrity will be necessary to achieve sustained integration within the joint, 
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especially with progressively increasing weight-bearing activities.  Secondly, cell differentiation 
was evaluated principally by analysis of gene expression, which may differ from changes in 
protein translation. While biochemical assays (i.e., hydroxyproline and sGAG content) 
demonstrated changes that were broadly congruent with mECM-mediated changes in gene 
expression, future studies will include Immunohistochemical staining and/or Western Blotting to 
confirm parallel changes in protein production. As mentioned above, additional investigation is 
underway to determine compositional differences between mECM extracts that may account for 
the region-specific bioactivities.  At the same time, it is important to consider the age of the 
ECM source.  Tottey et al.170 and Sicari et al.272 have shown that the age of the animal from 
which ECM biomaterials are derived can have significant effects on in vitro stem cell behavior 
and in vivo wound healing, respectively.  While similar studies have not been performed using 
meniscal ECM as a biomaterial, other studies have shown that the phenotype of ECM changed as 
part of meniscal degenerative changes with aging.273,274 For these reasons, mECM of this study 
was derived from young, adult cows without macroscopic evidence of joint injury or 
degeneration. Whether use of tissues from younger animals would provide greater biologic effect 
is a subject of ongoing research. 
4.1.5 Conclusions 
In conclusion, mECM represents a highly bioactive tissue extract that promotes differentiation 
towards region-specific cell phenotypes. Using a 3D hBMSC-based hydrogel construct in vitro, 
the inner mECM was found to enhance fibrocartilaginous differentiation, while the outer mECM 
promoted a more fibroblastic phenotype. Taken together, these results suggest the feasibility of 
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fabricating bioactive scaffolds using region-specific meniscus mECM preparations for meniscus 
tissue engineering. 
4.2 REGION-SPECIFIC BIOACTIVITY OF SOLUBLE INNER AND OUTER 
MENISCAL-DERIVED EXTRACELLULAR MATRICES IN PHOTOCURABLE 
METHACRYLATED GELATIN (GELMA) HYDROGELS 
4.2.1 Introduction 
The menisci of the knee, crescent-shaped fibrocartilaginous tissues interposed between the 
articular surfaces of the femur and tibia, must resist compressive, tensile, and shear forces in 
order to efficiently distribute tibiofemoral contact stresses and maintain joint health.51,275 As with 
other musculoskeletal tissues, the complex structure of the meniscus imparts a unique function, 
allowing the meniscus to facilitate efficient articulation of the tibiofemoral joint. A gradient of 
decreasing collagen type II and proteoglycan content exists when moving from inner meniscal 
regions towards the periphery, while the outer region is principally composed of aligned type I 
collagen fibers capable of resisting hoop stresses arising from joint loading.53-55,276 The region-
specific differences in ultrastructure and biochemical composition correspond to differences in 
cell phenotype; inner meniscal cells possess a round morphology reminiscent of articular 
chondrocytes while cells of the outer meniscus are found between aligned collagen fibers, similar 
to fibroblasts of tendon or ligament.51,275 Similarly, cells of the inner region express higher levels 
of collagen type II and aggrecan while cells of the outer region express greater collagen type I.56   
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Given the rapid onset of joint degeneration experienced with the loss of meniscal 
function,57,277 coupled with the limited availability and narrow inclusion criteria associated with 
meniscal allograft transplantation, tissue engineers have sought to develop novel biomaterials to 
serve as a meniscus substitute.278 Decellularized menisci derived from animal sources have been 
explored, as the removal of cellular material could mitigate any adverse immune response while 
preservation of tissue ultrastructure and biochemical composition could maintain meniscal 
function and promote region-specific differentiation of infiltrating host cells. However, the dense 
collagenous extracellular matrix of native menisci necessitates relatively harsh decellularization 
protocols with resulting losses in proteoglycan content and the associated compressive moduli of 
inner meniscal regions.94,279 Despite these alternations in ultrastructural and biochemical 
properties, infiltration of seeded cells is still limited.86,93   
Enzymatic digestion (e.g., pepsin) of decellularized meniscus extracellular matrix can 
produce a thermoresponsive hydrogel capable of delivering exogenous cells to a meniscal lesion 
while theoretically retaining meniscus-specific bioactive motifs capable of directing 
fibrocartilaginous neotissue formation.109 However, Lin et al.114 reported that pepsin digestion of 
extracellular matrices offered negligible advantage over collagen type I in terms of promoting 
proliferation, migration, and multilineage differentiation of mesenchymal stem cells (MSCs). 
Conversely, a urea-soluble fraction of ECM has been demonstrated in several studies to promote 
differentiation of MSCs towards tissue-specific (i.e., homologous) phenotypes.113-115 Most 
recently, we demonstrated that urea-soluble extracts of the inner and outer meniscus ECM could 
promote region-specific gene expression of MSCs seeded in a photocrosslinked polyethylene 
glycol diacrylate (PEGDA) hydrogel (Section 4.1).  Expanding on these findings, this study 
explores the effect of urea-soluble extracts of the inner and outer meniscus ECM in promoting 
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fibrochondrogenic differentiation of MSCs seeded in a visible light (VL) photoinducible 
methacrylated gelatin (GelMA) hydrogel. GelMA hydrogels have been shown to support robust 
chondrogenesis of encapsulated MSCs134 while the use of a VL-activated photoinitiator obviates 
concerns of UV light-induced mutagenesis or cytotoxicity.280 We hypothesized that the ECM 
extracts would promote region-specific cell phenotypes, with the inner and outer ECM extracts 
respectively enhancing chondrogenic and fibrochondrogenic differentiation of MSCs seeded in 
GelMA hydrogels. 
4.2.2 Methods 
4.2.2.1 Overview of experimental design  Urea-soluble extracts from the decellularized ECM 
of inner and outer regions of juvenile bovine menisci were isolated and characterized. The 
biological effects of ECM extracts on human bone marrow MSCs were evaluated in both 2D and 
3D in vitro cultures. MSCs were cultured on 2D plastic in the presence of ECM-supplemented 
media; assays for cell morphology, metabolism, and gene expression were performed up to 7 
days. Additionally, MSCs were cultured in ECM-enhanced GelMA hydrogels for up to 42 days 
to determine the region-specific bioactivity of the ECM extracts, as evaluated by measures of 
gene expression, histology, immunohistochemistry, biochemical composition, and mechanical 
properties. 
4.2.2.2 ECM decellularization  Menisci were procured from hindlimbs of 6-8 week old 
cows (Research 87, Boylston, MA) and stored in a protease inhibitor solution (phosphate-
buffered saline, 1X PBS; 5 mM ethylenediaminetetraacetic acid, EDTA; 0.5 mM 
phenylmethylsulfonyl fluoride, PMSF) at -20°C until use. Once thawed, menisci were halved, 
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coarsely minced (Figure 25A-C), and decellularized by adapting a previously established 
method.115 Briefly, 4 g of minced tissue was agitated for 24 hours at 4°C in 40 ml of protease 
inhibitor solution containing 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA), followed 
by 3 washes (30 minutes each at 4°C) in 1X PBS.  Subsequently, 40 ml of Hanks Buffered Salt 
Solution (HBSS, Thermo Fisher Scientific, Pittsburgh, PA, USA) supplemented with 200 U/ml 
DNase and 50 U/ml RNase (Worthington, Lakewood, NJ, USA) was added to the tissue, with 
continuous agitation for 12 hours at room temperature. The tissue was washed six times in 1X 
PBS, as above, before freezing and subsequent lyophilization. Native and decellularized tissues 
were evaluated for histological appearance, cellular content, and biochemical composition, 
including total collagen and sulfated glycosaminoglycan (sGAG) content, as described below. 
4.2.2.3 Histology of native and decellularized ECM  Native and decellularized tissues 
were fixed in 10% phosphate-buffered formalin, serially dehydrated, embedded in paraffin, and 
then sectioned (6 µm thickness) with a microtome (Leica RM2255, Leica Biosystems, Buffalo 
Grove, IL, USA). Samples were rehydrated and stained with haematoxylin & eosin (H&E, 
Sigma-Aldrich) or 4’,6-diamidino-2-phenylindole, dilactate (DAPI, Life Technologies, Carlsbad, 
CA, USA). H&E-stained samples were photographed using an Olympus SZX16 stereo 
microscope while DAPI-stained sections were visualized with an Olympus CKX41 inverted 
microscope using fluorescent excitation at 405 nm.   
4.2.2.4 Biochemical composition of native and decellularized ECM  To determine the 
biochemical composition of native and decellularized tissues, dry samples were digested 
overnight at 65°C at a concentration of 10 mg/ml in a digestion buffer (pH 6.0) containing 2% 
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papain (v/v, from Papaya latex, Sigma-Aldrich), 0.1 M sodium acetate, 0.01 M cysteine HCl, and 
0.05 M EDTA. The pH was then adjusted to 7.0 through addition of concentrated NaOH. sGAG 
content was quantified with a Blyscan Assay according to the manufacturer’s instructions 
(Biocolor, Carrickfergus, United Kingdom). dsDNA content was determined using the Quant-iT 
Picogreen dsDNA assay (Life Technologies). Total collagen was determined using a modified 
hydroxyproline assay. Briefly, 200 μL of each sample was hydrolyzed with an equal volume of 4 
N NaOH at 121°C for 75 min, neutralized with an equal volume of 4 N HCl, and then titrated to 
an approximate pH of 7.0. The resulting solution was combined with 1.2 mL chloramine-T (14.1 
g/L) in buffer (50 g/L citric acid, 120 g/L sodium acetate trihydrate, 34 g/L NaOH, and 12.5 g/L 
acetic acid) and allowed to stand at room temperature for 30 min. The solution was then 
combined with 1.2 mL of 1.17 mM p-dimethylaminobenzaldehyde in perchloric acid and placed 
in a 65°C water bath for 20 minutes.  200 µL of each sample was added to a clear 96-well plate, 
in duplicate, and absorbance at 550 nm was read. PureCol bovine collagen (3.2 mg/ml, 
Advanced Biomatrix, Carlsbad, CA, USA) was serially diluted to provide a standard curve 
ranging from 0 to 1000 µg/ml.  
4.2.2.5 Solubilization of decellularized ECM  Decellularized tissues were cryomilled into 
a fine powder (Spex Freezer Mill 8670, Metuchen, NJ, USA) and urea-soluble extracts of the 
decellularized ECM of inner and outer meniscal regions were obtained using a previously 
described method (Figure 25D-F).115 Briefly, 4 g of wet decellularized ECM powder was 
agitated for 3 days at 4°C in 40 mL of 3 M urea dissolved in water. The suspension was 
centrifuged for 20 minutes at 1500g and the supernatant was transferred to benzoylated tubing 
(Sigma-Aldrich) and dialyzed against ddH2O for 2 days at 4°C, changing the water every 8 
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hours. The dialyzed ECM extract was transferred to centrifugal filter tubes (3000 MWCO; EMD 
Millipore, Billerica, MA, USA) and spin-concentrated approximately 10-fold at 1500g for 60 
minutes. The final ECM extract was filter-sterilized through a PVDF syringe filter unit (0.22 µm; 
EMD Millipore). Protein concentration was determined by BCA assay (Thermo Fisher 
Scientific) and aliquots of 1000 µg/ml were stored at -80°C until further use. Before use in 
experimental studies, aliquots prepared from three different batches were pooled. 
In preliminary studies, decellularized ECM was alternatively solubilized by pepsin 
digestion using an established protocol.104,150 In particular, ECM powders were enzymatically 
digested in a solution of 1 mg/mL porcine pepsin (Sigma-Aldrich) in 0.01 N HCl for 48 hours at 
room temperature under continuous stirring. The resulting ECM slurries (Figure 25F) were 
neutralized by addition of one-tenth digest volume of 0.1 N NaOH and one-ninth digest volume 
of 10X PBS, then further diluted by addition of 1X PBS. These pepsin-solubilized ECM 
hydrogels (i.e., imAP, omAP) were principally composed of collagen (Figure 25G,H) and were 
inferior to urea-soluble extracts in promoting cell proliferation and fibrochondrogenic 
differentiation (data not shown); they were therefore excluded from additional experiments. 
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Figure 25. Solubilization of ECM from inner and outer meniscus. (A) Whole menisci were 
obtained from 6-8 week old cow hindlimbs, (B) halved, and (C) manually minced (8-27 mm3).  
Following decellularization, (D) tissues were cryomilled and soluble fractions were obtained 
either by (E) urea-extraction (supernatant was retained, yellow line) or (F) acid-pepsin digestion.  
SDS-PAGE of (G) inner meniscus and (H) outer meniscus tissues and soluble preparations 
demonstrate that urea extraction retained low- and moderate-weight proteins while pepsin 
digestion yielded mostly collagen. 
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4.2.2.6 SDS-PAGE and growth factory analysis of ECM    Dry samples of native 
inner and outer meniscus ECM, and their corresponding urea-soluble and pepsin-digested 
extracts were suspended in TM buffer (Total Protein Extraction Kit, EMD Millipore). 30 µg 
total protein was mixed with LDS loading buffer and reducing agent (NuPAGE; Life 
Technologies, Carlsbad, CA, USA) and heated for 10 minutes at 70°C. Protein was loaded into a 
pre-cast 10-well NuPAGE 4-12% Bis-tris Minigel (Life Technologies) and separated by 
electrophoresis in MOPS running buffer for 50 minute at constant 200V. The gel was 
washed several times in water and photographed using a CCD camera gel imaging system 
(FOTODYNE, Hartland, WI, USA).   
Additionally, the growth factor contents of the urea-soluble extracts of the inner meniscus 
(imECM) and outer meniscus (omECM) were measured using a Human Growth Factor 
Array (RayBiotech, Norcross, GA), according to the manufacturer’s instructions.   
4.2.2.7 Bioactivity of meniscus ECM extract in 2D culture  Human bone marrow MSCs 
were obtained as previously described.114 All experiments were performed with passage 3 (P3) 
MSCs pooled from 3 patients (31 year old female, 42 year old male, 44 year old 
male) undergoing total hip arthroplasty with Institutional Review Board approval 
(University of Washington and University of Pittsburgh). To determine the effect of ECM 
extracts on MSC morphology and metabolism, cells were suspended in growth medium 
(DMEM, 10% FBS, 1% Anti-Anti; Life Technologies) and plated in 6-well culture plates 
at a density of 1 x 103 cells/cm2. One day following cell seeding, growth medium was 
replaced with serum-free medium (DMEM, 1% Anti-Anti, 1% Insulin-transferrin-selenium 
[ITS]; Life Technologies) with or without ECM extract supplementation. There were three 
media conditions – (1) serum-free control, (2) supplementation with 50 µg/ml imECM, and 
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(3) supplementation with 50 µg/ml omECM. Media were changed every 2 days. On days 1, 3,
and 7, an MTS assay (CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay; 
Promega, Madison, WI) was performed according to manufacturer’s instructions. 
To determine the effects of ECM extracts on gene expression, 2 x 104 cells/cm2 were 
plated in 6-well culture plates and cultured up to 7 days, as described above. On days 1, 3, and 7, 
total RNA was isolated from cells using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA) 
and reverse transcribed into cDNA through use of SuperScript III first-strand synthesis kit 
(ThermoFisher Scientific, Pittsburgh, PA, USA). Quantitative real-time polymerase chain 
reaction (qPCR) was performed using SYBR® Green master mix (Applied Biosystems, Foster 
City, CA) on a StepOnePlus Real-Time PCR system (Applied Biosystems). Relative expression 
of each target was calculated using the ∆∆CT method with the arithmetic average of GAPDH and 
r18S expression used as the endogenous reference. For 2D cultures, expression of Sox9, collagen 
type 2 (Col2), collagen type 1 (Col1), aggrecan (Acan), and Runx2, was analyzed. Additional 
targets were included for 3D cultures, as described below. Primer sequences are listed in 
Supplemental Table 4. As significant differences across treatment groups were only seen at day 
3, expression levels were normalized against day 3 controls.  
4.2.2.8 Bioactivity of meniscus ECM extract in 3D GelMA hydrogels  Methacrylated gelatin 
(GelMA) was synthesized as previously described.134 ECM-enhanced GelMA contained 500 
µg/mL of imECM or omECM, whereas controls were supplemented with an equal volume of 1X 
PBS. MSCs were suspended in the liquid GelMA (8% w/v suspended in HBSS with 0.2% v/v of 
visible light-sensitive photoinitiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate, LAP) at 
15 x 106 cells/ml. 50 µL of the cell suspension was distributed to silicone molds measuring 5 mm 
diameter x 2 mm depth and exposed to high intensity visible light (450-490 nm) for 2 minutes to 
induce photogelation.  MSC-encapsulated hydrogels were transferred to 6-well plates previously 
coated with silicone (Sigmacote, Sigma-Aldrich) to prevent cell migration and adhesion onto the 
plastic surface, and cultured for up to 42 days in full chondrogenic medium (DMEM, 1% Anti-
Anti, 10 µg/ml ITS, 0.1 µM dexamethasone, 40 µg/mL proline, 50 µg/mL ascorbate-2-phopshate, 
10 ng/mL Transforming Growth Factor β3 [TGF-β3; Peprotech, Rocky Hill, NJ, USA]). 
Medium was changed every 2-3 days. The MSC-encapsulated hydrogels were collected at 
various time points and analyses for gene expression, biochemical composition, histology and 
immunohistochemistry, and compressive mechanical properties. 
4.2.2.9 Gene expression and biochemical composition analyses   On days 1, 7, 21, 
and 42, total RNA was isolated from constructs through sequential use of Trizol 
(Thermo Fisher Scientific) and RNeasy Plus Mini Kit (Qiagen), according to manufacturers’ 
protocols. Reverse transcription and qPCR was performed as described above.  Expression of 
the following gene targets was determined for the 3D constructs – Sox9, Col2, Col1, Acan, 
Collagen type 6 (Col6), Runx2, cartilage oligomeric matrix protein (COMP), platelet-derived 
growth factor receptor (PDGFR), tissue inhibitor of metalloproteinase 2 (TIMP2), scleraxis 
(Scx), tenascin C (Tnc), and fibromodulin (Fmod). Primer sequences are listed in Supplemental 
Table 4.  On days 21 and 42, constructs were digested overnight in papain using the 
protocol described in Section 4.2.3.4. Total sGAG and dsDNA contents were determined, 
allowing subsequent normalization of sGAG by dsDNA. 
4.2.2.10 Histological and immunohistochemical analysis Histological sections were 
prepared on days 21 and 42 using a similar protocol  as  performed  when  characterizing the
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appearance of native and decellularized meniscal tissues described in Section 4.2.3.3. Following 
rehydration, samples were stained with Safranin O/Fast Green (Electron Microscopy Sciences, 
Hatfield, PA USA); nuclei were counterstained with Haemotoxylin. For 
immunohistochemical staining of collagens type 2 and type 1, antigen retrieval was achieved by 
incubation of slides for 30 minutes at 37°C in Chondroitinase ABC (100mU/ml, Sigma) and 
Hyaluronidase (250 U/ml, Sigma) suspended in 0.02% bovine serum albumin (BSA). 
Endogenous peroxidases were blocked with 3% H2O2 (in methanol). Non-specific binding 
was blocked with 1% horse serum. Samples were then exposed to rabbit anti-human collagen II 
primary antibody (ab34712; Abcam, Cambridge, MA, USA) diluted 1:400 or rabbit anti-
human collagen I primary antibody (ab34710; Abcam) diluted 1:100 in 1% horse serum 
overnight at 4°C. Equine biotinylated secondary antibody binding, signal amplification, and 
visualization, were achieved through the use of VectaStain Universal Elite ABC Kit (Vector 
Laboratories, Burlingame, CA, USA) in accordance with the manufacturer’s instructions. 
Nuclei were counterstained with Haematoxylin QS (Vector). 
4.2.2.11 Compressive mechanical testing  On day 42 the cylindrical specimens were 
tested in uniaxial unconfined compression with a Bose Electroforce 3200 series II (resolution 
1nm, load cell 1000g) while kept moist in 1X PBS. After a preload of 0.1% strain, samples were 
compressed at a 0.01mm/s rate reaching a strain of 20% The elastic modulus E was extracted by 
linear fitting of the final part of the stress-strain curve near the maximum load, as previously 
described. 
4.2.2.12 Statistical analyses  Comparisons across multiple conditions or time points 
were made using a one-way or two-way analysis of variance (ANOVA) with Tukey post-hoc 
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testing for multiple comparisons.  When comparing two conditions, a Student’s t-test was 
performed. Data are presented as mean ± standard deviation. Sample sizes are indicated in figure 
legends. Statistical significance was considered p < 0.05. 
4.2.3 Results 
4.2.3.1 Characterization of inner and outer meniscal ECM  Histological staining
confirmed the absence of cell nuclei in both inner and outer meniscal ECM following the 
decellularization protocol (Figure 26A-H), with a corresponding reduction in dsDNA content 
(Figure 26I; Native vs. Decellularized – Inner: 555.1 ± 62.5 ng/mg vs. 7.7 ± 6.2 ng/mg, p < 
0.001; Outer: 616.3 ± 52.1 ng/mg vs. 11.7 ± 9.4 ng/mg, p < 0.001).  Decellularized ECM from 
both inner and outer regions possessed a lower sGAG content than native tissues (p < 0.001). 
However, native and decellularized inner meniscal ECM possessed higher sGAG content (31.7 ± 
6.8 µg/mg and 9.7 ± 5.9 µg/mg, respectively) than outer meniscal ECM (10.0 ± 1.7 µg/mg and 
1.6 ± 1.0 µg/mg, respectively) at the corresponding step (Figure 26J).  Conversely, the total 
collagen content was equivalent between meniscal regions and remained constant following 
decellularization (Figure 26K). As compared to native inner and outer meniscus, imECM and 
omECM possessed a reduced concentration of high molecular weight proteins, including 
collagen, but abundant low and moderate weight proteins and/or fragments (Figure 25G,H). The 
growth factor array revealed differences in several proteins when comparing imECM with 
omECM; notably, basic fibroblast group factor (bFGF) was found only in omECM while TGF-β 
concentrations were higher in imECM (Table 2).   
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Figure 26. Characterization of native and decellularized meniscus tissue. (A, B) H&E and 
(C, D) DAPI staining of native inner and outer meniscus, respectively.  (E, F) H&E and (G, H) 
DAPI staining of decellularized tissues.  Arrows indicate blood vessels found in outer meniscus 
(B, F); Scale bar = 500 µm.  (I) dsDNA content of native and decellularized meniscus; dotted 
line at 50 ng/mg is established threshold for sufficient decellularization. (J) sGAG content. (K) 
Total collagen content.  For biochemistry assays, n = 8-10 per condition.  # p < 0.001, significant 
difference between native and decellularized tissue from a given region. Lines over bars indicate 
significant difference between regions for a given step, p < 0.05.  
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Table 2. Growth factor concentrations (pg/mL) in imECM and omECM extracts 
4.2.3.2 ECM-induced proliferation and differentiation in 2D culture  Over a 7 day culture, 
imECM and omECM enhanced cell proliferation of MSCs as shown through phase contrast 
microscopy (Figure 27A-C) and MTS assay. imECM and omECM supplementation increased 
cell proliferation equivalently at all time points (Figure 27D). On day 3, both imECM and 
omECM increased expression of Sox9, Col2, and Col1, although statistically significant 
increases were only achieved with imECM supplementation (p < 0.05). Acan and Runx2 
expression did not significantly differ across conditions (Figure 27E).  
Protein imECM omECM 
bFGF 0.0 362.6 
EGF R 3.1 0.0 
EG-VEGF 0.1 0.0 
IGFBP-4 3.6 0.0 
Insulin 0.0 36.6 
NT-3 3.4 3.2 
OPG 59.0 54.7 
SCF 1.8 1.1 
SCF R 16.3 0.0 
TGFb1 241.7 140.9 
TGFb3 29.3 0.0 
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Figure 27. Bioactivity of soluble ECM extracts on MSCs in 2D culture. (A-C) phase contrast 
microscopy. (D) MTS assay measuring cell metabolism; n = 6-8 per condition; Lines indicate 
significant difference between groups on given day, p < 0.05. (E) Gene expression analysis on 
day 3; n=3 independent trials, each performed in biological triplicate; Lines indicate significant 
difference between groups, p < 0.05. 
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4.2.3.3 Gene expression of MSC-seeded hydrogels enhanced with ECM  MSC-seeded 
GelMA hydrogels supported robust upregulation of chondrogenic proteins Col2 and Acan over a 
42 day culture, with modest increases in Col1 and Runx2 expression in all groups on days 7 and 
21, before returning to baseline on day 42 (Figure 28). imECM upregulated Sox9 over controls 
and omECM on day 1, while both ECM groups were slightly inferior to controls on day 7 before 
demonstrating equivalency across groups at later time points. Both ECM groups strongly 
upregulated Col2 expression on day 7, while only imECM supplementation maintained enhanced 
expression over controls on day 21. Conversely, omECM upregulated Col1 expression on day 1, 
while both imECM and omECM had significantly reduced Col1 expression on day 21 compared 
to controls.  imECM and omECM increased Acan expression on day 21, but differences were not 
statistically significant. Col6 expression across all groups was downregulated after day 1, with 
further reductions induced by omECM on days 7 and 21. Runx2 expression was decreased in 
omECM and imECM constructs on days 7 and 42, respectively, as compared with controls. 
Expression of additional genes associated with the fibrochondrocyte and fibroblast phenotype 
were measured (Supplemental Figure 8). ECM supplementation had either a negligible or 
inhibitory effect on gene expression as compared against controls.  
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Figure 28. Gene expression in MSC-GelMA constructs. n=3 independent trials, each 
performed in biological triplicate; Lines indicate significant differences between groups, p < 
0.05. 
4.2.3.4 Immunohistochemical and histological staining of hydrogels  At day 21, positive 
staining for collagen type 2 was found in the pericellular region, with cells near the construct 
perimeter demonstrating more intense staining (Figure 29A-F). ECM-supplemented constructs 
exhibited greater Col2 deposition, with imECM constructs superior to omECM constructs. By 
day 42, all groups demonstrated robust Col2 staining distributed throughout the entire construct 
area (Figure 29G-L). Nevertheless, regions of reduced intensity were found between intensely 
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staining clusters only in Controls, while imECM and omEMC constructs exhibited a more 
homogenous distribution of intense Col2 staining. 
Proteoglycan deposition, as visualized through Safranin O staining, paralleled Col2 
staining (Figure 30). imECM and omECM constructs showed greater staining on day 21, as 
compared to Controls, with imECM producing the greatest effect (Figure 30A-F). However, by 
day 42, all constructs showed intense proteoglycan deposition and differences among groups 
could not be qualitatively appreciated (Figure 30G-L). Supplementation of the culture medium 
with TGF-β3 was essential for such robust anabolic effects. When constructs were cultured in 
the absence of TGF-β3, no proteoglycan deposition was noted in Controls by day 42 
(Supplemental Figure 9A,F). Inclusion of imECM and omECM within hydrogels produced a 
small degree of proteoglycan deposition surrounding the cells (Supplemental Figure 9B-C, G-
H), but staining intensity was much less that of constructs cultured in full chondrogenic medium 
(Figure 30). Acellular constructs, even with ECM supplementation, were negative for 
proteoglycan deposition (data not shown), suggesting that imECM and omECM promoting 
proteoglycan deposition through cell-mediated synthesis.   
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Immunohistochemical staining for Col1 produced a pattern opposite to that seen for Col2 
and proteoglycan (Figure 31). In particular, imECM constructs showed the least Col1 deposition 
on days 21 and 42. Controls and omECM constructs showed comparable Col1 deposition on day 
21 (Figure 31A-F), but by day 42, Col1 staining intensity was most profound in Controls 
(Figure 31G-L).   
Figure 29. Immunohistochemical staining of collagen type 2. (A-F) Constructs on day 21; (A-
C) Low magnification, scale bar = 1 mm; Area of magnification shown by black box; (D-F) High 
magnification, scale bar = 200 µm. (G-L) Constructs on day 42; (G-I) Low magnification, scale 
bar = 1 mm; Area of magnification shown by black box; (J-L) High magnification, scale bar = 
200 µm. 
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Figure 30. Safranin O staining. (A-F) Constructs on day 21; (A-C) Low magnification, scale 
bar = 1 mm; Area of magnification shown by black box; (D-F) High magnification, scale bar = 
200 µm. (G-L) Constructs on day 42; (G-I) Low magnification, scale bar = 1 mm; Area of 
magnification shown by black box; (J-L) High magnification, scale bar = 200 µm. 
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Figure 31. Immunohistochemical staining of collagen type 1. (A-F) Constructs on day 21; (A-
C) Low magnification, scale bar = 1 mm; Area of magnification shown by black box; (D-F) High 
magnification, scale bar = 200 µm. (G-L) Constructs on day 42; (G-I) Low magnification, scale 
bar = 1 mm; Area of magnification shown by black box; (J-L) High magnification, scale bar = 
200 µm. 
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4.2.3.5 Biochemical composition and compressive moduli of hydrogels  The 
biochemical composition of constructs mirrored the histological findings. Total sGAG content 
was significantly increased in imECM and omECM constructs on days 21 and 42 (Figure 32A), 
while no significant difference in dsDNA content was found over time or among groups (Figure 
32B). Nevertheless, when sGAG content was normalized to cellular content, only imECM 
constructs were significantly elevated over Controls on day 21, while both ECM-supplemented 
groups were significantly increased by day 42 (Figure 32C). Similar to histological findings, 
acellular constructs possessed negligible sGAG content, even when supplemented with imECM 
or omECM (data not shown). imECM and omECM constructs trended towards higher 
compressive moduli than Controls, but these differences were not statistically significant (Figure 
32D). 
Figure 32. Biochemical composition and compressive modulus of MSC-GelMA constructs. 
(A) Total sGAG content. (B) Total dsDNA content.  (C) sGAG normalized by DNA.  (D)
Compressive modulus on day 42.  n=8-10 samples per condition; Lines indicate significant 
difference between groups, p < 0.05. 
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4.2.4 Discussion 
Expanding on recent work (Section 4.1), this study investigated the region-specific bioactivity of 
urea-extracted decellularized meniscal ECM when presented to human bone marrow MSCs in 
both 2D and 3D cultures. In preliminary studies, pepsin-digested hydrogels derived from 
decellularized inner and outer meniscal ECM did not affect fibrochondrogenic differentiation of 
MSCs when added as a medium supplement in 2D culture or when seeded with MSCs as a 3D 
scaffold. The absence of fibrochondroinductivity of pepsin-digested hydrogels agrees with recent 
work by Visser et al.111 in which supplementation of GelMA hydrogels with pepsin-soluble 
meniscal ECM did not alter gene expression or protein deposition. As seen both grossly and by 
SDS-PAGE, pepsin digestion yields a slurry that contains predominantly collagen. Conversely, 
urea-extracted fractions are enriched for low- to moderate-weight proteins, the combination of 
which has been previously demonstrated to promote tissue- or region-specific differentiation of 
MSCs.113-115 Similarly, in this study, imECM and omECM were found to promote MSC 
proliferation and upregulation of fibrochondrogenic markers Sox9, Col2, and Col1, when added 
as a supplement in 2D culture. Based upon these findings, the bioactivities of imECM and 
omECM were further explored when mixed with GelMA hydrogels. 
GelMA is a versatile biomaterial capable of supporting robust chondrogenic 
differentiation of MSCs after rapid light-activated gelation.133,134 Additionally, the inclusion of a 
water-soluble, visible light-responsive photoinitiatior (i.e., LAP) obviates concerns of possible 
cellular damage caused by UV light exposure, as required by most photoinitiators (e.g., 
Irgacure).280 While the effect of meniscal ECM supplementation on MSC-seeded GelMA 
hydrogels was previously unexplored, functionalization of GelMA with particulated (hyaline) 
cartilage ECM has been reported to enhance chondrogenesis of encapsulated MSCs.101,281  
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Although the particulated ECM was presumably chondroinductive due to retention of intrinsic 
chondrogenic cues, robust chondrogenesis required stimulation with exogenous TGF-β3. A 
similar result was found in this study. Namely, imECM and omECM supplementation of MSC-
GelMA constructs produced faint but discernible deposition of proteoglycan in the pericellular 
regions when cultured in medium without TGF-β3. In contrast, the addition of TGF-β3 to culture 
medium produced robust chondrogenic differentiation of MSCs, as determined by multiple 
assays. Supplementation with ECM, especially imECM, enhanced chondrogenic gene expression 
at earlier time points (i.e., days 7 and 21), translating into sustained increases in collagen type II 
and sGAG deposition at days 21 and 42. In accordance with the chondrocytic phenotype of inner 
meniscal cells, these results suggest that imECM is capable of supporting region-specific 
differentiation of MSCs. While omECM supplementation significantly upregulated Col1 
expression on day 1, the effect was not sustained over the culture period.  Rather, constructs 
supplemented with either imECM or omECM demonstrated repressed Col1 expression at day 21, 
as compared against Controls. Similarly, ECM-mediated decrements in collagen type I 
deposition were seen on day 42 by immunohistochemistry.  In our previous study (Section 4.1), 
in which PEGDA hydrogels were supplemented with meniscal ECM, omECM constructs 
showed sustained upregulation of Col1 expression for at least 7 days, although longer time points 
were not examined nor was immunohistochemistry performed.  Although the mechanistic basis 
underlying these discrepancies was beyond the scope of this study, differences in hydrogel 
composition (i.e., GelMA vs. PEGDA), meniscal ECM-hydrogel interactions, cell 
adhesion/morphology, and duration of TGF-β3 exposure, may have contributed to the inability 
of omECM to maintain an increased Col1 expression.   
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imECM transiently upregulated expression of chondrogenic regulator Sox9 on day 1, 
with negligible differences across groups at later time points. Interestingly, cells isolated from 
the inner and outer regions of native menisci were reported to express equivalent levels of Sox9, 
suggesting minimal influence of Sox9 in distinguishing region-specific phenotypes.56 
Conversely, Vanderploeg et al.53 showed collagen type VI to be concentrated in inner meniscal 
regions and localized to the pericellular matrix; in this study, omECM supplementation 
downregulated Col6 expression, as compared with Controls and imECM constructs. In 
examining additional putative meniscal cell markers,65 ECM supplementation tended to have a 
negligible or inhibitory effect at early time points, with broad equivalency across groups by day 
42. To the extent that these transcriptional changes are meaningful for tissue engineering
application remains uncertain, given the paucity of studies characterizing the phenotypes of cells 
across various meniscus regions. 
On the other hand, the homogenous distribution of MSCs within GelMA hydrogels 
clearly does not recapitulate the complex fibrous architecture of native menisci.51,275 In 
particular, tie fibers are known to extend radially from the central meniscus to the periphery, 
binding aligned circumferential fibers and allowing efficient transformation of compressive loads 
into hoop stresses.275 In an in vitro model, Puetzer and Bonassar138 demonstrated that simulated 
tibiofemoral loading of an engineered meniscus composed of high density collagen seeded with 
meniscal fibrochondrocytes began to recapitulate the fibrous ultrastructure and resulting 
mechanical anisotropy of native menisci. Whether mechanical loading could orchestrate similar 
structural organization of MSC-GelMA constructs is unknown.    Alternatively, ECM-
supplemented hydrogels may be combined with electrospun nanofibers to better reconstitute the 
structural and biochemical properties of the meniscus.282,283 Baek et al.284 fabricated multilayered 
129 
scaffolds with alternating layers of electrospun nanofibers and MSC-seeded alginate hydrogels, 
which allowed tunable tensile anisotropy depending on fiber orientation. However, compressive 
mechanical properties were not measured. In this study, compressive moduli of constructs (~ 40-
50 kPa) did not differ across groups, but were congruent with reported values for GelMA 
hydrogels.134,285 Unlike other studies, in which values of compressive modulus correlated with 
glycosaminoglycan content,137,285 the greater total and normalized sGAG content of ECM-
supplemented constructs did not significantly enhance compressive moduli, suggesting that the 
differences in sGAG content or the resulting hydrogel architecture were insufficient to produce 
discernible changes in mechanical properties. As with fiber architecture, mechanical loading has 
been found to further increase sGAG deposition, with concurrent improvements in compressive 
mechanical properties.138,286 Controlled mechanical loading as part of post-surgical rehabilitation 
may serve as a viable strategy to further enhance the compressive moduli of the remodeling 
hydrogels, as the GelMA constructs are presently weaker than native menisci (~ 100-500 
kPa).51,256,287 Additional improvements in initial material properties of GelMA constructs may 
also be realized by adding exogenous hyaluronic acid and/or modifying the decellularization 
process so as to retain a higher endogenous sGAG content within the resulting ECM extracts.288 
As demonstrated by Levett et al.,285 supplementation of GelMA hydrogels with exogenous 
hyaluronic acid, rather than endogenous production by encapsulated cells, produced the greatest 
improvements in compressive mechanical properties. 
While preservation of the biophysical and biochemical motifs of the native ECM is 
presumed to most faithfully reconstitute tissue-specific cell phenotypes, limitations in whole 
meniscus decellularization, as described in the introduction, necessitate further processing to 
improve cell infiltration.6 To that end, one must balance the disruption of native motifs with 
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technical and biological utility gained by further ECM processing. Retention of higher sGAG 
content within ECM extracts may not only improve mechanical properties of constructs but may 
also enhance chondrogenic differentiation of seeded cells. For instance, hyaluronan of native 
ECM, through binding to the CD44 receptor of the cell surface, can upregulate 
chondrogenesis.143,289 Alternatively, exogenous hyaluronan/sGAG could be added to the present 
formulation of ECM-supplemented GelMA for possible benefit. Nevertheless, future 
investigations elucidating the essential elements of the meniscus ECM governing cell phenotype 
are essential to further guide tissue engineering applications aimed at restoring the structure and 
function of the meniscus, in turn preserving joint integrity.  
4.2.5 Conclusions 
In this study, urea-extracted fractions of decellularized inner and outer meniscal ECM enhanced 
proliferation and fibrochondrogenic differentiation of human bone marrow MSCs cultured on 
plastic. GelMA hydrogels supplemented with soluble ECM fractions accelerated chondrogenic 
differentiation of seeded MSCs as determined by analyses of gene expression, protein deposition, 
and biochemical composition of the constructs. Upregulation of chondrogenesis was most 
pronounced with inclusion of imECM. While ECM supplementation alone enhanced 
chondrogenic differentiation, robust effects required supplementation of media with exogenous 
TGF-β3. Given these findings, photocrosslinkable hydrogels enhanced with imECM, TGF-β3, 
and MSCs, may offer a potential therapeutic strategy to promote region-specific neotissue 
formation when combined with surgical repair of tears in the avascular meniscal region.    
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5.0  DISCUSSION 
5.1 SUMMARY 
Through a series of studies, we demonstrated that urea-extracted ECM derived from 
decellularized tendon and cartilage could promote homologous (i.e., tissue-specific) 
differentiation of MSCs when cultured on 2D surfaces and as 3D pellets, which mimic 
aggregating mesenchymal cells of the developing limb.  Endogenous TGF-β is necessary, but not 
sufficient, to promote ECM-mediated tissue-specific differentiation.  When added to tissue-
appropriate biomimetic scaffolds – aligned nanofibrous scaffolds and photocurable GelMA 
hydrogels – tECM and cECM enhanced tissue-specific differentiation of MSCs and interacted 
synergistically with exogenous TGF-β.  Applying these findings to a single tissue with noted 
regional variation, we found that urea-extracted ECM derived the inner and outer meniscus was 
capable of promoting region-specific differentiation of MSCs seeded in PEGDA hydrogels.  
When combined with MSC-GelMA constructs, both imECM and omECM promoted 
chondrogenesis, an effect more strongly promoted by imECM. The discrepancy between GelMA 
and PEGDA may be attributable to the presence or absence of bioactive motifs with the polymer 
backbone of gelatin and PEG, respectively.  Taken together, these studies begin to clarify the 
mechanisms by which ECM may exert tissue-specific bioactivity while also supporting the use 
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of urea-extracted fractions of soluble ECM to promote homologous cell phenotypes in adult stem 
cells seeded in biomimetic scaffolds. 
In addition to the immediate challenges and future directions articulated within the 
discussion of each specific aim, broader considerations about the future direction of tissue 
engineering are expanded upon below. 
5.2 FUTURE PERSPECTIVES 
This following section contains material from the publication: 
Yang G, Lin H, Rothrauff BB, Yu S, Tuan RS. (2016) Multilayered 
polycaprolactone/gelatin fiber-hydrogel composite for tendon tissue engineering.  Acta 
Biomaterialia.  [Epub ahead of print] PMID: 26945631 
5.2.1 ECM-Enhanced Biomaterials – Getting Closer to Native Structure & Function 
The results contained herein suggest that urea-extracted ECMs can further enhance tissue-
specific differentiation in MSCs seeded in biomimetic scaffolds by ostensibly recapitulating the 
biophysical and biochemical cues of native ECM to a greater degree than the scaffolds or soluble 
ECMs alone.  However, the fold-changes in gene expression induced by soluble ECMs were, 
depending on the experiment, often far lower than those induced by exogenous TGF-β.  While 
this likely suggests the necessity of including exogenous growth factors to induce robust 
neotissue formation for tissue engineering application, this interpretation must be tempered by 
the fact that in vitro assays do not necessarily predict in vivo responses, especially when 
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considering the complexity of tissue regeneration.  Nevertheless, the synergism consistently 
found between soluble ECMs and exogenous TGF-β support their combined use with 
biomimetic scaffolds, as the ECM component may accelerate tissue-specific differentiation 
and/or diminish the heterologous bioactivity that is possible when applying pleotropic growth 
factors such as TGF-β. 
Assuming an intention of perfectly matching the many properties of native tissues, the 
engineered constructs developed in these studies fall short on several parameters.  In particular, 
the mechanical properties of both electrospun nanofibers and photocrosslinked GelMA hydrogels 
are inferior to native tendon/ligament and cartilage/meniscus, respectively.  Incorporation of 
textile patterns (e.g., weaving, braiding, etc.)290,291 or the use of novel polymers292 could enhance 
initial mechanical properties, although the effect of these alternative strategies on cell behavior 
would require further investigation.  At the same time, the application of mechanical stimulation 
in a bioreactor could accelerate ECM synthesis by seeded cells, augmenting the initial strength of 
the biomaterials.128,138 Mechanical stimulation mimicking physiological loading parameters has 
also been found to independently promote homologous differentiation.  Interestingly, 
compressive mechanical loading was shown to prevent hypertrophy of MSCs seeded in 
biomimetic hydrogels, perhaps serving as a strategy to mitigate the upregulation of hypertrophic 
and osteogenic markers seen above with cECM supplementation.286,293 These considerations, 
while important for iterative improvements in tissue engineering applications as presently 
practiced, belie broader questions that must be answered if we seek to bring the promise of tissue 
engineering to fruition.  I’ve attempted to identify some of these issues in the following 
discussion. 
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5.2.2 Top-Down vs. Bottom-Up Tissue Engineering 
5.2.2.1 Top-down tissue engineering (reverse engineering)  Tissue engineering has 
largely confronted its task through a top-down approach; that is, the deconstruction of a tissue 
into individual elements, which can be mimicked through engineering methods or procured from 
simpler biological systems (e.g., recombinant proteins), then reassembled under the intention of 
rebuilding the system.  The work performed herein is very much a part of this paradigm.  The 
biophysical elements of a tissue were mimicked through engineered scaffolds (i.e., electrospun 
nanofibers and porous hydrogels) and the biochemical components were extracted from 
decellularized xenogeneic tissues (obviating an adverse immune response) then combined with 
biomimetic scaffolds with the intention of more faithfully reconstituting tissue structure and 
function than what might be possible with the use of a single or combined growth factor.  The 
results suggest that the urea-extracted fraction of decellularized tissues does indeed promote 
tissue-specific differentiation of adult MSCs across multiple 3D microenvironments, supporting 
the hypothesis.  Although still preliminary, experiments further suggest that the provision of 
tissue-specific ECM may direct the bioactivity of a pleotropic growth factor (e.g., TGF-β) 
towards homologous effects.  Thus a synergistic effect occurs.  However, the combination of 
urea-extracted ECM with a homologous biomimetic scaffold did not always suppress 
heterologous gene express.  To the extent that these non-specific effects compromise the ultimate 
cell phenotype is unknown.  At the same time, it is also unclear to what degree an engineered 
construct must recapitulate all elements of the native tissue to provide in vivo benefit.294 
Advances in biomaterial fabrication methods continue to expand the elements of the 
native tissue that can be mimicked.116,295 For instance, there have been numerous reports of 
composite scaffolds that combine electrospun fibers with hydrogels, thereby replicating the 
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viscoelastic properties several musculoskeletal soft tissues.296  In fact, our lab recently developed 
a composite scaffold of aligned electrospun nanofibers coupled with visible light-responsive 
GelMA hydrogel (Figure 33).297 GelMA provides cell-binding motifs otherwise absent on 
polyester nanofibers.  Additionally, the ability of the hydrogel component to undergo 
photogelation allows for rapid cell encapsulation that would be required in single-stage point-of-
care procedures.  As we recently showed, not only are these composite scaffolds cytocompatible, 
but the cells elongate in the direction of the fibers and are subsequently responsive to exogenous 
tenogenic cues (e.g., TGF-β) (Figure 34).297 Equally promising are hydrogels with reversible 
chemistries that can more precisely regulate cell spreading, ligand presentation, and matrix 
mechanics.298 At the same time, advances in 3D printing technologies facilitate the production of 
human-scale tissue constructs with structural integrity.299 Nevertheless, it is increasingly 
appreciated that cell morphogenesis and differentiation can require stringent spatial arrangements 
of ECM motifs,300 and our understanding of cell-matrix interactions on a single cell level is still 
limited. 
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Figure 33. Composite fiber-hydrogel scaffold fabrication. Dual electrospinning was employed 
to fabricate a scaffold containing PCL and mGLT fibers (Insert 1). Dry scaffold was wetted with 
aqueous photo-initiator solution (Insert 2) and then photocrosslinked by visible light (VL) to 
retain the gelatin (Insert 3). 
 
Fortunately, tissue matrix arrays and other approaches for engineering nanoscale 
microenvironmental cues are growing in sophistication.301,302 In combining these 3D tissue 
arrays with systems-level analyses, it may be possible to gain greater insight into the mechanistic 
basis by which biophysical cues modulate cell signaling pathways.302,303 However, in order to 
understand the multifactorial complexities inherent in cell-matrix interactions, the prevailing 
reductionistic paradigm, which has provided innumerable insights regarding the function of 
individual elements of the system, must be expanded.  Namely, systems biology could provide 
newfound sophistication in top-down tissue engineering approaches. Systems biology seeks to 
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reveal how interactions among elements of a system (i.e., signaling network  cell  tissue  
organ  organism) can give rise to emergent properties of the system.304,305 To do so, 
computational models are compared with experimental findings through an iterative process of 
testing, validation, and retesting, with experimental findings guided an increasingly predictive 
model.  Thus far, systems biology has been almost exclusively applied to signaling networks 
with cell lines grown in 2D culture.  With exponential increases in complexity with every step in 
scale, the application of systems biology to tissue engineering is highly challenging but greatly 
needed.306,307 
 
Figure 34. Tendon-like features of MSCs encapsulated in composite scaffold. (A) Fiber 
alignment observed by SEM. (B) Elongated morphology of human adipose stem cells (hASCs) 
aligned in the direction of fibers (green, F-actin; blue, nuclei). (C) Anisotropy based on tensile 
strength properties measured by mechanical testing along two directions (Longi. vs. Cross). (D) 
Significant upregulation of tendon markers scleraxis (SCX) and tenascin C (TNC) upon 
treatment with exogenous tenogenic factor TGF-β3, measured by real-time PCR analysis. 
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5.2.2.2   Bottom-up tissue engineering (developmental engineering)  The confluence of 
advancing engineering technologies with greater computational sophistication will, in theory, 
ultimately permit the fabrication of biomaterials possessing nano- through meso-scale 
microenvironmental cues capable of fully reconstituting the complex structure and function of 
native tissues.  However, the timescale on which such promise becomes reality is presently 
unknown.  An alternative to the top-down approach to tissue engineering is a bottom-up 
approach, perhaps more simply referred to as developmental engineering.  Developmental 
engineering approaches tissue engineering by trying to recapitulate the elements and sequences 
of embryogenesis.308,309 Importantly, recapitulation of development requires more than merely 
the provision of individual elements known to play a role in tissue formation.  Rather, it 
necessitates nascent cells and a minimum set of conditions from which a robust, semi-
autonomous process emerges, with the cells and their evolving ECM culminating in an 
engineered tissue indistinguishable from the native tissue.  In so far as the molecular mechanisms 
governing differentiation of progenitor cells are known (and can be replicated in vitro), it may be 
possible to recapitulate tissue formation in vitro.30 As an example, the steps governing the 
specification and maturation of chondrocytes starting from mesodermal progenitors are 
moderately well established.310-312 When replicated, large, stratified, and mechanically functional 
human cartilage has been grown in vitro and successfully transplanted (and integrated) into a 
focal chondral defect.313,314 While the molecular mechanisms regulated tendon cell fate are less 
well known, increasing knowledge of the subject may allow similar applications to tendon tissue 
engineering in the near future.315,316  
At the same time, there is growing understanding of the role of mechanical loading in 
both developmental processes and tissue engineering.317 While it is has been known for decades 
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that the recovery of tissue structure and function is best achieved by progressively increasing the 
loading demands on a healing tissue, 318 the systematic application of physical therapy to 
improve the integration and maturation of tissue engineered constructs remains in the nascent 
stages.  Termed “regenerative rehabilitation”, this evolving paradigm seeks to use the body as a 
bioreactor, through the prescriptions of a physical therapist, to provide controlled mechanical 
loads to the healing tissue. 319,320 As the field is still in the earliest stages, future studies should 
seek not only to elucidate the in vivo dynamics experienced by musculoskeletal tissues, but also 
how these in situ stresses and strains affect ex vivo engineered constructs.  In theory, this would 
allow a range of ‘physical therapy’ protocols to be tested ex vivo in microphysiological systems, 
with experimental results informing the predictive models of in vivo responses. 
5.2.3 In Situ Tissue Engineering 
As highlighted above, in vitro recapitulation of the molecular events guiding cell differentiation 
during development may provide us with engineered constructs that more faithfully match the 
structure and function of native tissues, while in vivo mechanical loading (the parameters of 
which could one day be guided by ex vivo modeling in microphysiological systems) could mimic 
the mechanical environment guiding tissue formation during organogenesis. However, the 
diseased microenvironment can drastically differ from that of the developing embryo.  Therefore, 
the direct application of knowledge concerning the molecular mechanisms of development may 
not prove fruitful in promoting tissue regeneration in a diseased state. While musculoskeletal soft 
tissues do not possess a strong intrinsic healing capacity, increases in progenitor cells at the time 
of injury have been found for many of these tissues, including tendon,321 meniscus,64 and 
cartilage.36,38 Taken together, the restoration of tissue integrity following injury or disease may 
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be better served by mitigating the factors that actively inhibit tissue healing rather than seeking 
to stimulate repair in the face of these unabated impediments.   
Although not the focus of this work, biological scaffolds composed of tissue-derived 
ECM promote constructive remodeling (i.e., improved healing) in part by altering the 
characteristics of the default inflammatory response following injury.322 In particular, the 
proportion of a particular macrophage phenotype appears to dictate the quality of healing, with 
M2 macrophages serving a more anti-inflammatory role while M1 macrophages are pro-
inflammatory and seem to promote generic scarring.173 ECM scaffolds, when sufficiently 
decellularized, have been shown to promote a stronger M2 macrophage polarization,168,323 with 
macrophage phenotype actually predicting the quality of healing.172 Immunomodulation of the 
injured microenvironment, either through ECM-based scaffolds, pharmaceuticals, or engineered 
biomaterials, may be necessary in order to create a more permissive microenvironment in which 
conventional tissue engineering approaches can then achieve maximum benefit.324-326   
Should such strategies prove feasible, the injury-mediated increase in local progenitor 
cells may be sufficient for intrinsic healing to proceed.  However, numerous strategies are 
currently being explored that can enhance the recruitment of reparative cells to the wound site, 
including partial digestion of the dense collagen ECM or chemokine-guided localization.327-330 
Novel biomaterials capable of sequential release of chemotactic and differentiation factors could 
theoretically attract progenitor cells to the wound site and subsequently direct tissue-specific cell 
differentiation and neotissue formation.331-333 What role urea-extracted ECM could play in these 
processes is the subject of future investigations. 
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5.2.4 Conclusions 
The field of tissue engineering continues to expand at an exponential pace, filling both patients 
and providers alike with hope for medical breakthroughs.  But at present, the treatment options 
for orthopaedic soft tissues are starkly limited. Ever evolving engineering techniques allow 
greater and greater fidelity in mimicking the structure and function of musculoskeletal tissues, 
but no effort thus far has yielded an engineered construct matching that of native tissues.  In 
bridging that gap, the combination of solubilized ECM with biomimetic scaffolds may allow 
closer replication of the biophysical and biochemical cues of the native ECM while permitting 
the flexibility and tunability of synthetic materials.  However, the precision to which engineered 
constructs must match the structure of native tissues in order to promote in vivo regeneration 
remains a vexing question.  Furthermore, it is increasingly apparent that the complex 
microenvironment of the diseased state, coupled with the immune response to engineered 
constructs, will have tremendous bearing on bringing the promise of tissue engineering to 
fruition.   To that end, continued efforts to elucidate the molecular bases of musculoskeletal 
development and disease are of the utmost importance, in turn guiding the development of 
therapeutics that seek to alleviate suffering and improve function.  It is a challenge most worthy 
of my decades to come. 
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SUPPLEMENTAL FIGURES 
 
 
Supplemental Figure 1. (A) Schematic depicting the functionalization of primary amines of 
gelatin with methacrylate pendant. (B) Exposure of liquid GelMA to visible light, in the presence 
of a water-soluble photoinitiator (0.5% LAP) causes rapid photocrosslinking to form hydrogel. 
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Supplemental Figure 2. The effect of TGF-β inhibition on biochemical content of MSC pellets. 
Medium conditions for pellet cultures were further supplemented with 10 µM SB-431542. 
Pellets supplemented with cECM exhibited elevated (albeit blunted) total sGAG and dsDNA 
content compared to other medium conditions (p < 0.05, n=9); dotted line indicates sGAG and 
dsDNA contents of control medium (without SB-431542).   
 
 
 
 
 
 
 
 
 
 
 
144 
Supplemental Figure 3. MSC-seeded hydrogels derived from pepsin-digested ECM. MSCs 
were seeded in 5 mg/mL hydrogels of Collagen 1 (Control), tAP, and cAP.  ECM-derived 
hydrogels showed negligible tissue-specificity compared to collagen controls (p < 0.05, n= 9) 
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Supplemental Figure 4. Macroscopic image of femoral condyles from young (6-8 weeks) and 
mature (2-3 years) cows.  The osteochondral interface is distinct in adult animals but indistinct in 
young animals, with clear vasculature seen in dissected cartilage pieces. 
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Supplemental Figure 5. Characterization of tECM and other medium supplements by SDS-
PAGE. tECM contains abundant low molecular weight proteins (<50 KD) that are absent in 
collagen type I solution (Col I) and FBS. 
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Supplementary Figure 6. Real-time PCR analysis of SOX9 expression revealed that tECM 
alone possessed little inductive effect on chondrogenesis of ASCs in 2D culture compared to 
other treatment groups with TGF-β3. The expression level of SOX9 was significantly higher in 
cell pellets cultured in standard chondrogenic medium (Chondro Medium) than in all other 
groups. **, p<0.01; N=3. 
148 
Supplemental Figure 7. Morphology of ASCs cultured on scaffolds. hASCs seeded on 
random scaffolds (upper left, SEM) exhibited polygonal shape without uniformity in orientation 
(upper right, confocal microscopy). In contrast, hASCs seeded on aligned scaffolds (lower left, 
SEM) adopted an elongated morphology and were orientated in the direction of the fibers (lower 
right, confocal microscopy; F-actin, green; nuclei, blue; microfiber, red). 
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Supplemental Figure 8. Gene expression analysis of MSC-GelMA constructs.  n=3 independent 
trials, each performed in triplicate; Lines indicate significant difference between groups, p < 
0.05. 
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Supplemental Figure 9. Safranin O staining of constructs cultured in TGF-β3-free medium on 
day 42. (A-C) Low magnification, scale bar = 1 mm; Area of magnification shown by black box; 
(F-H) High magnification, scale bar = 200 µm. 
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SUPPLEMENTAL TABLES 
Supplemental Table 1. Primer sequences for qPCR. 
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Supplemental Table 2. Growth factor concentrations (pg/mL) in 500 µg/mL of soluble ECM 
extracts 
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Supplemental Table 3. Primer sequences for qPCR. 
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Supplemental Table 4. Primer sequences for qPCR. 
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